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1 Introduction
Over the past two decades there has been a new and increased interest in the
concept of causality in statistics. This interest has lead to various new ap-
proaches for deﬁning and studying causality in statistical terms. In medical
sciences, studies are typically driven by questions that are causal in nature,
for example questions of treatment eﬀects or the eﬀect of some other inter-
vention. Causality can, however, also be about understanding mechanisms,
addressing questions about possible mediating variables and their eﬀects.
For example, considering which variables the treatment eﬀect is mediated
through. Answering any such questions about causality systematically re-
quires extensions to standard statistical methods.
Infectious disease modelling is a ﬁeld that has also received an increasing
amount of attention over the last decades with the spread of HIV, the recent
swine ﬂu pandemic, the threat of avian ﬂue and many others. Infectious
diseases have re-emerged as a threat to western countries; and there has
also been an increasing focus on Third World medical problems. As medical
research in Western countries traditionally has had chronic diseases such as
heart disease and cancer as the major areas of focus, new statistical models
are required to understand the spread of infectious diseases.
The main aims of this thesis are to study approaches for estimating the
causal eﬀect of treatment on survival from HIV/AIDS using data from ob-
servational studies, and the concepts of epidemic growth rates and dynamic
modelling of infectious diseases. These aims are met by studying methods for
estimating the causal eﬀect of treatment, and addressing the concept of direct
and indirect eﬀects by dynamic path analysis, using data from the Swiss HIV
Cohort Study. Epidemic growth rates and reproduction numbers are studied
together with a dynamic model for HIV/AIDS progression and models for
estimating inﬂuenza related excess mortality using Norwegian surveillance
data.
A recurrent theme in this thesis is infectious disease, and the methods
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discussed are all applied in either a HIV/AIDS or inﬂuenza setting. However,
the methods cover diﬀerent areas of statistical and mathematical modelling;
the two most important are infectious disease modelling and causality. There
are four papers included in this thesis, and even though Paper 3 and Pa-
per 4 address causal inference directly, Paper 1 and Paper 2, considering
infectious disease modelling, complement these last two papers with regard
to causality in infectious diseases. Paper 1 and Paper 2 illustrate how in-
fectious disease modelling is strongly connected to a causal way of thinking.
There are obvious similarities between mechanistic causality as discussed in
Paper 4, and modelling infectious diseases using dynamic multi-stage mod-
els, as in Paper 1. Paper 2 is an example of how questions in medical
science are causal in nature, and how these questions can be addressed using
public health surveillance data.
In Paper 1 we study the use of epidemic growth rates and reproduction
numbers, with application to a multi-stage model for HIV/AIDS progression.
In Paper 2 we estimate inﬂuenza related excess mortality, epidemic growth
rates and reproduction numbers using Norwegian surveillance data. In Pa-
per 3 we introduce a method for estimating the causal eﬀect of treatment
using data from a HIV/AIDS cohort study, while in Paper 4 we build on
some of the ideas from the previous paper to analyze the same type of data
using dynamic path analysis. The four papers follow at the end of this thesis.
The outline for the rest of the thesis is as follows: Section 2 gives an in-
troduction to infectious disease, focusing on HIV/AIDS and inﬂuenza in par-
ticular. Modelling of infectious disease, HIV/AIDS progression, inﬂuenza re-
lated excess mortality, reproduction numbers and growth rates are discussed
in Section 3. Causality and causal modelling are discussed in Section 4, in
particular with respect to counterfactual causality and to methods for mak-
ing causal inference from observational studies. Direct and indirect eﬀects
are discussed in Section 5, emphasizing graphical models and dynamic path
analysis. The four papers are summarized in Section 6, while a ﬁnal discus-
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sion is found in Section 7.
2 Infectious diseases
Infectious diseases are diseases caused by a transmissible agent replicating in
an infected host. New infections occur when susceptible hosts are exposed to,
and then acquire the agent. Agents can transmit from one host to another,
creating a chain of transmissions in the population; this is the most distinctive
feature of infectious disease epidemiology [1].
There are many reasons why infectious disease has received more atten-
tion in recent years: inﬂuenza and HIV have already been mentioned, while
other examples are the occurrence of resistant tuberculosis, the SARS epi-
demic, the fear of bio-terrorism, multi-resistant microbes in hospitals and
various sexually transmitted diseases [2]. However, as the methods in this
thesis are all applied to either data on HIV/AIDS or inﬂuenza, the following
discussion will be limited to these two infectious diseases.
2.1 HIV/AIDS
Human immunodeﬁciency virus (HIV) is a virus that attacks the human im-
mune system by infecting cells such as the helper/inducer T cells. These cells
are also designated as CD4 cells. The stage of HIV infection is typically mea-
sured by the CD4 cell count and by the viral load (the number of copies of
HIV RNA in the blood). The most severely aﬀected patients are prone to re-
peated opportunistic infections and neoplasms, characterized as the acquired
immune deﬁciency syndrome (AIDS) [3]. Since the discovery of HIV and
AIDS in the early eighties, the disease has spread worldwide at an alarming
rate. The pandemic was in 2002 estimated to have infected 42 million people,
increasing at a rate of 5 million new infections per year, and causing 3 million
deaths per year – the majority were in the sub-Saharan Africa [4]. In most
western countries, the HIV epidemic is mostly associated with certain risk
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groups, such as men who have sex with men and injecting drug users. Recent
treatment, using highly active antiretroviral treatment (HAART), and often
referred to as just antiretroviral treatment (ART), has shown a substantial
reduction in disease progression among infected patients [5], but a vaccine
has yet to be discovered.
Historically, HIV/AIDS surveillance in the western countries focused on
monitoring the AIDS incidence, and even after the HIV test became available,
reports of HIV incidence were slow to be adopted. However, after the intro-
duction of HAART, disease progression became less predictable and AIDS in-
cidence no longer represented transmission trends. HIV case-reporting there-
fore became more urgent. HIV prevalence was typically monitored through
surveys among diﬀerent risk groups [6]. Today there are many huge multi-
center cohort studies, national and international collaborations, gathering
relevant information about HIV infected individuals. Examples include the
Multicenter AIDS Cohort Study (MACS) [7] in the USA and the Swiss HIV
Cohort Study [8].
The methods in Paper 1, Paper 3 and Paper 4 in this thesis are all
applied to HIV/AIDS.
2.2 Inﬂuenza
Inﬂuenza is an infection of the respiratory tract caused by inﬂuenza viruses.
The viruses are transmitted by contact, droplet and airborne transmission,
and are highly transmissible in high density communities [9]. The infection
is typically characterized by sudden-onset fever, dry cough, nasal conges-
tion, headache, muscle pain, weakness, and loss of appetite [10]. Inﬂuenza is
usually self-limited with recovery in 2–7 days. Pneumonia is a common com-
plication. Most patients make a full recovery, but the severity of inﬂuenza
epidemics vary with virus type, and for certain high risk groups inﬂuenza can
be a deadly disease. The highest mortality is found among the elderly and
patients with underlying severe diseases, and for these risk groups annual in-
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ﬂuenza vaccines are recommended in many countries [11]. Seasonal inﬂuenza
usually causes annual outbreaks of varying length and severity during the
winter months in the northern hemisphere. Occasionally, new virus variants
appear, to which few or no-one is immune, possibly causing an inﬂuenza
pandemic. There were three big inﬂuenza pandemics in the last century: the
Spanish ﬂu in 1918–19, the Asian ﬂu in 1957–58 and the Hong Kong ﬂu in
1968–70. More recently, we had the so-called swine ﬂu pandemic emerging
from Mexico in 2009.
Most developed countries monitor inﬂuenza activity by measuring the
number of patients seeking health care, the virologically conﬁrmed cases or
by other markers for inﬂuenza-like illness (ILI). In Norway from 1998, weekly
numbers on inﬂuenza have been collected from sentinel practices using the
number of ILI cases per total number of consultations. Mortality due to
inﬂuenza is, on the other hand, harder to discern, and inﬂuenza is rarely
recorded as the cause of death in Norway [11].
The methods in Paper 2 in this thesis are applied to Norwegian ILI data.
3 Infectious disease modelling
The notion of infectious disease modelling is most often used for infectious
disease transmission models, compartment models or dynamic systems ex-
plaining and predicting the movement of infection through a population over
time [1]. Even though there is a long history of mathematical modelling in
epidemiology, going back to Bernoulli in the 18th century, the dynamic sys-
tem approach ﬁrst became popular in the 1920s. Since then, the methodology
surrounding this type of models has been exposed to numerous conceptual
and technical developments [4]. The models are used to predict the course
of epidemics and to investigate the eﬀect of change in model parameters.
Changes in model parameters can represent change of risk-seeking behavior,
the introduction of vaccines, medication or any other countermeasure.
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Infectious disease modelling has become a huge ﬁeld, and the methodology
covered in this thesis will be limited to certain groups of models. We will con-
sider the type of compartment models mentioned in the introduction of this
section, which are used to model HIV/AIDS progression in Paper 1. Other
types of models are models for estimating excess mortality using epidemic
surveillance data and data on overall mortality, as studied in Paper 2. These
latter models are somewhat on the side of what is usually denoted infectious
disease modelling, as they do not model the spread or progression of disease
as the compartment models above. Instead, they are based on ﬁtting models
to observed epidemic curves using regression techniques. Other important
concepts within infectious disease modelling are reproduction numbers and
epidemic growth rates. Both Paper 1 and Paper 2 discuss the estimation
and use of these quantities.
Examples of other areas in infectious disease modelling, not covered in
this thesis, are expansions of the mentioned compartment models into multi-
host models, models with stochastic dynamics, spatial models and network
models. For an introduction to these topics, see for example Keeling and
Rohani [4].
3.1 Compartment models
Generally, transmission models for infectious disease consider members of the
population to fall into compartments, stages or states such as ‘susceptibles’,
‘infectious’ and ‘recovered’ [1]. This example of compartments is used in the
famous SIR model by Kermack and McKendrick from the 1920s [4]. Simple
transmission models for infectious disease use only two or three compart-
ments, but many more compartments can be used in more complex situa-
tions. An example of a basic SIR model is illustrated in Figure 1. Here, S,
I and R denote the susceptible, infectious and recovered part of the pop-
ulation. Correspondingly, the notation S(t), I(t) and R(t) is used for the
number of individuals in each of the three compartments. λ(t) and γ are
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transition rates, speciﬁcally the rate of infection and the rate of recovery.
The infection rate λ(t) is dependent of the number of susceptible individu-
als in the population, usually by λ(t) = k · s(t), where k is the number of
new infections transmitted by one individual per unit time and s(t) is the
proportion of susceptible individuals in the population at time t.

 
Figure 1: An example of a simple SIR model with transition rates λ(t) and γ.
The SIR model shown in Figure 1 can be modeled using the ordinary
diﬀerential equations
dS
dt
= −λ(t)I(t),
dI
dt
= λ(t)I(t) − γI(t),
dR
dt
= γI(t).
Despite their simplicity, these diﬀerential equations cannot be solved explic-
itly and are therefore solved numerically [4]. The models can of course be ex-
tended and altered in various diﬀerent ways, for example by including demog-
raphy (individuals entering and leaving the system with certain rates), other
dependencies between compartments or by including more compartments.
For further reading on the SIR model and related models, see Paper 1 and
also Keeling and Rohani [4] or Diekmann and Heesterbeek [12].
3.1.1 A model for HIV/AIDS progression
One extension of the simple compartment models discussed in the previous
subsection is described in Paper 1, as a model for HIV disease progres-
sion among homosexual men in England and Wales. See Figure 2 for an
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Figure 2: A generalized SIR model for HIV/AIDS progression.
illustration (ﬁgure reprinted from Paper 1).
The model in Figure 2 is a generalized SIR model [13] and, compared with
the model in Figure 1, it has been extended with demography and the use
of a multi-stage Markov model to replace the single infectious compartment.
The added demographic parameters include N , m and m0. N is the number
of individuals entering the susceptible stage per unit time, while m is rate
to which the susceptibles die, or leave the system uninfected, and m0 is the
background mortality rate. Note that a background mortality rate, such
as m0, should generally aﬀect all states where individuals are still alive.
However, for simplicity, m0 is only added to state 11, 12 and 13 in the model
in Figure 2. The rate m0 is small compared to the other transition rates
and it makes no practical diﬀerence whether to include them. Including such
rates could, on the other hand, be essential for other exposure groups, such
as injecting drug users [14].
The other parameters λ(t), ai, bi, di, fi, gi and mi for all i are transition
rates, and h1, h2 and h3 are factors decelerating, or modifying, certain tran-
sition rates. The model is based on the Markov model in Aalen et al. [18],
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and the parameters are based on previous estimated rates and on published
studies of HIV/AIDS. See Paper 1 for further details.
3.2 Estimating inﬂuenza-related excess mortality
Another type of model that can be applied to infectious diseases are models
for estimating the excess mortality attributable to disease using surveillance
data on disease incidence and numbers of overall deaths. In Paper 2, such
models are used to estimate the excess mortality due to inﬂuenza. As in this
paper, the discussion in the following section will focus mainly on applications
to inﬂuenza. These models could however also be used to estimate other
types of excess mortality. For example, they are commonly used to estimate
excess mortality related to heat waves as in Fouillet et al. [15]. Generally, the
models will not only apply to excess mortality, but also to other equivalent
situations, such as estimating excess hospitalization [16].
Excess mortality is usually deﬁned as the diﬀerence between the observed
number of deaths and the expected number of deaths, where the latter is the
expected number of deaths without the occurrence of inﬂuenza. There are
various ways of quantifying this number of expected deaths, but they can
generally be divided into three types of models.
In the most simple classic epidemic-threshold models, the excess mortality
is deﬁned as all deaths exceeding a seasonal baseline threshold, found for
example by averaging over periods without inﬂuenza outbreaks.
Models based on cyclic regression or time series calculate this threshold
in a more advanced manner, modelling seasonal variation using paramet-
ric models. Typically, the parts of the mortality and inﬂuenza time series
where epidemics are meant to have occurred are excluded from the estimating
process [17].
Other models are based on Poisson regression, negative binomial regres-
sion or other related regression models. Unlike the cyclic regression and
time series models, they model the mortality using inﬂuenza activity as an
9
explanatory variable, together with other important explanatory variables.
The models used in Paper 2 fall into this category. Using these models
the excess mortality is estimated as the diﬀerence between the observed and
the predicted mortality from the regression model, leaving out the inﬂuenza
contribution.
Beside the aforementioned diﬀerences between these three types of mod-
els, they also vary signiﬁcantly within these categories. The diﬀerences will
typically lie in the model speciﬁcation, the type of marker for inﬂuenza ac-
tivity and other variables aﬀecting mortality, which additional covariates are
being included, reasoning surrounding what periods should be excluded from
the estimating process, whether weekly data are used or data with another
resolution and so on. All of these aspects could aﬀect the excess mortal-
ity estimate. The principal advantage of using models based on Poisson or
negative binomial regression is that other competing causes for excess mor-
tality, such as the incidence of other diseases or factors such as temperature,
can be included as covariates. Also, modelling the seasonality using mark-
ers means that parametric shapes of seasonality do not need to be assumed.
However, if data only are available for short time periods, the ability to add
such parametric assumptions would be an advantage.
For further discussion and references, see Paper 2 as well as Nunes et
al. [17].
3.3 Reproduction numbers and epidemic growth rates
A common goal when modelling infectious disease is to quantify the growth
of an epidemic, usually by estimating reproduction numbers. These are im-
portant quantities because they give a better understanding of the magnitude
and the potential course of an epidemic. For example, calculating reproduc-
tion numbers from compartment models can give information about what
type of countermeasures would be suﬃcient for preventing outbreaks. Repro-
duction numbers and epidemic growth rates are among the topics in Paper 1
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and Paper 2.
Generally, a reproduction number is the average number of secondary
infections caused by one infected individual during the infectious period.
The term basic reproduction number (R0) is used for the reproduction
number of one individual introduced into a completely susceptible popula-
tion. In a homogeneous population with random mixing, where c is the
expected number of contacts per unit time, β is the probability that a con-
tact between a susceptible and an infected leads to transmission and D is
the average length of the infectious period, R0 can be calculated as [12,13]
R0 = cβD
Alternatively, for the basic SIR model in Figure 1, using the corresponding
notation, R0 is given by
R0 =
k
γ
. (3.1)
For basic SIR models with demography or other basic compartment models,
similar expressions for R0 exists.
If R0 > 1, the introduction of an infected individual in a population
has the potential to set oﬀ an epidemic. Otherwise, if R0 < 1, an added
infectious individual would produce less than one new infection on average,
and the infection will die out. In other words, R0 = 1 is the threshold that
decides whether an epidemic is possible.
If the population is not completely susceptible, the infected individual in
question will sometimes ‘try’ to infect an individual who is already infected.
The eﬀective reproduction number (Re(t)) [13] is the average number of new
infections caused by one individual introduced into such a population, and
can be calculated as
Re(t) = R0 · s(t), (3.2)
where s(t) again is the proportion of susceptibles at time t.
The reproduction numbers R0 and Re are the most common reproduction
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numbers being used, and they have an important role in infectious disease
modelling and assessment. There are however other variants, such as the
actual reproduction number (Ra(t)), which describes the actual spread of an
epidemic that has already occurred. Ra is calculated as the average number of
secondary cases per case to which the infection has actually been transmitted
during the infectious period in a population [13,19]. For the basic SIR model,
the expressions for Ra(t) and Re(t) are identical, but this is generally not the
case for more complex models.
Another type of quantity that is related to the growth of an epidemic
is the epidemic growth rate. The intrinsic growth rate (r) [13] denotes the
growth rate at the very beginning of an epidemic outbreak. Here, the growth
is exponential, and the intrinsic growth rate corresponds to an exponen-
tial growth rate. The intrinsic growth rate r diﬀers from the reproduction
numbers in the way of describing epidemic growth. While the reproduction
numbers describe the reproduction over an individual’s infectious period, r
describes the immediate growth of the entire epidemic. For long lasting in-
fections, where disease progression can change, or be uncertain, r might be
a more meaningful quantity than reproduction numbers such as R0. An ob-
vious example of such a long lasting infection is HIV, where the situation for
infected individuals has changed when new treatment, such as HAART, has
become available.
For the basic SIR model in Figure 1, r is found by
r = k − γ. (3.3)
The growth rate can also be expressed as a time-dependent growth rate
(r(t)) [13]. For the same basic SIR model, r(t) is
r(t) = λ(t) − γ, (3.4)
or the diﬀerence between the ‘birth’ rate and ‘death’ rate of new infections
12
per unit time.
To read more about reproduction numbers and epidemic growth rates, see
Paper 1 or Diekmann and Heesterbeek [12]. In Paper 1 we also discuss how
to estimate these quantities in more advanced compartments models, while
estimation from observed data is discussed in both Paper 1 and Paper 2.
4 Causal inference
Saying something about the relationship between cause and eﬀect for certain
variables or events is one of the main aims of natural and social sciences,
including medical research. However, the methodology for extracting such
causal relationships has been the subject of ﬁerce debate over the years [20].
In statistics, maybe even more than in other ﬁelds, there has traditionally
been a very cautious attitude towards talking about causation, based on an
awareness of the fundamental diﬀerence between statistical association and
actual causal relationships [2]. This attitude has to some extent gradually
changed over the last decades, with what could be called a growing causal
movement within statistics. People like J. Pearl, J. M. Robins, D. B. Ru-
bin and others began to develop frameworks for causal thinking in statistics,
speaking of and deﬁning concepts like causal eﬀects. However, what statis-
ticians speak of under the causality banner varies. One categorisation is to
divide the topics into the following three areas of statistical causality: coun-
terfactual causality, graphical models and predictive causality [2].
The methods discussed in the following sections, and in Paper 3 and
Paper 4 fall within the ﬁrst two areas. The topics in this section are within
counterfactual causality, while Section 5.1 will touch on the area of graphical
models and the concepts of direct and indirect eﬀects.
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4.1 Counterfactual causality
The main objective in counterfactual causality is to measure the eﬀect of
some intervention, such as medical treatment or another preventive health
measure.
Take, for example, the causal eﬀect of treatment with regard to patients’
lifetime. Every patient i has two possible responses: one if the patient was
given treatment, Y1i, and one if the patient was not given treatment, Y0i.
Such responses are also called potential outcomes [20]. The causal eﬀect of
treatment for patient i is then merely
θi = Y1i − Y0i. (4.1)
Ideally, this would be the causal eﬀect we are interested in, but obviously
both potential outcomes are not possible to observe. One of the outcomes
can be observed, the other is counterfactual and cannot be observed, simply
because it does not exist. This has been called the fundamental problem of
causal inference [22], but it does not mean that causal inference is impossible.
The alternative to the causal eﬀect in (4.1) is to look at the average causal
eﬀect. If Y1 and Y0 are the potential outcome random variables, the average
causal eﬀect, often referred to as just the causal eﬀect, is [21]
E[θ] = E[Y1 − Y0] = E[Y1] − E[Y0]. (4.2)
The deﬁnition of a causal eﬀect in equation (4.2) could also be written
using do-operator notation, where setting a variable X to a value x is denoted
by do(X = x), or do(x) for short. Given two disjoint sets of variables X and
Y , where x1 and x0 are two distinct realizations of X, the causal eﬀect of X
on Y , θ, can be denoted by [20]
E[θ] = E(Y |do(x1)) − E(Y |do(x0)). (4.3)
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The average causal eﬀect from (4.2) or (4.3) is found as the average out-
come for patients receiving treatment minus the average outcome for patients
not receiving treatment. Models for estimating such eﬀects are called coun-
terfactual models or potential-outcome models. For these estimates to be
unbiased, there are two main assumptions which need to hold:
1. The stable unit treatment value assumption (SUTVA): The causal ef-
fect for a particular patient does not depend on assignments of other
patients and there are no hidden versions of treatment [23].
2. (Strong) ignorability: Treatment assignment T is independent of the
outcomes given a vector of all the observable covariates X, or (Y1, Y0) ⊥
T |X [21]. In other words: the treatment assignment mechanism can
be said to be ignorable, given all observed covariates.
The randomized controlled trial (RCT) has for long been seen as the gold
standard in medical research [24]. In RCTs the patients are randomly as-
signed to diﬀerent groups, such as a treatment group and a control group.
The resulting eﬀect estimate is then the diﬀerence between the mean re-
sponse in the diﬀerent groups. In this way, ideal RCTs fulﬁll the ignorability
assumption through the random treatment assignment. However, the ideal
set-up can be violated for many reasons; perfect control over patients is hard
to achieve, randomization into placebo groups is not always ethical, and
the presence of randomization itself might inﬂuence the participation in the
study. In other words, it is not always feasible to create a RCT. HIV treat-
ment is a good example of when random treatment assignment would not be
ethical: assigning a patient to placebo would be to deny the patient possible
life-saving treatment [20]. Studies of such treatment eﬀects would then have
to lean on observational studies.
Observational studies are empirical investigations of treatments, poli-
cies or exposures, and their eﬀects. The studies may have the same goal
as RCTs, but diﬀer in that the investigator cannot control the treatment
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assignment [25]. The main examples of such observational studies used in
this thesis are the many large HIV cohort studies, especially the Swiss HIV
Cohort Study [8] analysed in Paper 3 and Paper 4.
In an ideal RCT, because of the randomization, we have that association
is causation. This is not the case in observational studies. Here, in general
association is not causation. However, observational studies are often the
only alternative for causal inference, and there exist methods that permit
the estimation of causal treatment eﬀects from observational data, under
certain assumptions [26].
4.2 Causal inference from observational studies
To say something about the average causal eﬀect of an observed treatment
status variable D on an outcome variable Y in observational studies, the
treatment selection mechanism [21] has to be taken into the model. In other
words, the bias due to any lack of randomization has to be adjusted for.
For pre-treatment diﬀerences, there are two types of confounders creating
such selection biases: the observed or measured confounders, and the ones
not measured, but suspected to exist, the unobserved or unmeasured con-
founders. A goal in causal inference of observational studies is then to adjust
for all observed confounders, and to assess and reduce sensitivity to possibly
unmeasured confounders. The methodology needed to do this will vary with
the complexity of the treatment selection and the data.
If the treatment exposure is ﬁxed, and given that there are no unmea-
sured baseline covariates or model misspeciﬁcations, conventional methods
to adjust for confounding by baseline covariates such as stratiﬁcation, match-
ing and/or regression would give consistent estimators of the causal eﬀect.
However, when estimating the causal eﬀect of a time-varying treatment on
an outcome, conventional methods could fail to have a causal interpretation,
even when there are no unmeasured confounders, no model misspeciﬁcation,
and all of the time-dependent confounders are controlled for [28].
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HIV cohort data, such as the Swiss HIV Cohort Data, are a typical exam-
ple where such problems of time-dependent confounding are present. Time-
dependent confounding could be present when a variable, aﬀected by past
treatment, is both a predictor of future treatment and of outcome [29].
In the HIV cohort setting, patients are typically observed through re-
peated visits, where at each visit the treatment indicator variable and vari-
ables such as the outcome and other relevant covariates are updated. An
example of a time-dependent confounder would be the CD4 cell count, which
because treatment for HIV is not given before the patient is at a certain stage
of disease, is a predictor of future treatment and outcome (usually AIDS or
death). Also, treatment would again increase the CD4 count; past treatment
will aﬀect later CD4 levels. Methods for estimating the causal eﬀect of treat-
ment in the presence of time-dependent confounding in such datasets will be
the theme for the rest of this section.
4.2.1 Marginal structural models
The most established method for estimating the causal eﬀect of a time-
dependent exposure A on an outcome Y in the presence of time-dependent
confounding covariates L is probably the marginal structural model (MSM)
[29, 30]. Using the notations of Robins, Ak and Lk denote the values of the
time-dependent variables A and L at the discrete time point k, such as in
the kth month since start of follow-up.
The models are called marginal because they model the marginal distri-
bution of the counterfactual random variables Ya0=1 and Ya0=0, and struc-
tural because they model the probabilities of counterfactual variables, often
called structural models in econometrics and the social sciences [29]. The
parameters of the MSM can be estimated using so-called inverse probability
of treatment (IPT) weights, and implemented as an extension of standard
methods such as the Cox proportional hazards model.
One way to understand the MSMs and the IPT weighting procedure is
17
to think of the problem of unmeasured counterfactuals as a missing data
problem. Ideally we would want the ‘full data’, including all potential out-
comes for every individual, but in our observed data the counterfactuals are
obviously missing. However, the situation is similar to when dealing with
censored data, and a method for adjusting for dependent censoring such as
inverse probability weighting can be used.
Consider an observational study, such as a HIV cohort study, with non-
random and monotone missingness (if the patient drop out, he does not come
back). When dealing with dependent censoring, inverse probability of censor
(IPC) weights [31,32] are used to account for the missing observations in the
dataset. The idea is to ‘rebuild’ the dataset to what it would have looked
like without any censoring, by weighting each observed individual at time t
with the inverse probability of being observed at time t. This corresponds to
weighting each individual to account for the number of ‘similar’ individuals
who have dropped out. The probability of being observed, or 1 minus the
probability of being censored, could be estimated using logistic regression,
adjusting for all relevant covariates. In addition, inverse probability weights
are often stabilized to achieve greater eﬃciency (see next paragraph) [30].
Continuing with a notation similar to the one by Robins and Hernan, let
C(t) be 1 if a patient is censored at time t and 0 otherwise, V a vector of
time-independent baseline covariates, A¯(t) = {A(u); 0 ≤ u < t} the covariate
history up to time t, and similarly for C¯(t) and L¯(t). A¯(0) and C¯(0) is by
deﬁnition 0. The stabilized IPC weight for patient i at time t is
wi(t)
=
t∏
k=0
P [C(k) = 0|C¯(k − 1) = 0, A¯(k − 1) = a¯i(k − 1), V = vi)]
P [C(k) = 0|C¯(k − 1) = 0, A¯(k − 1) = a¯i(k − 1), L¯(k − 1) = l¯i(k − 1)]
.
(4.4)
Using unstabilized weights would correspond to using the weights from equa-
tion (4.4), but replacing the numerator with 1. This way of weighting for
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dependent censoring using stabilized IPC weights is used in both Paper 3
and Paper 4 in this thesis.
A MSM can be ﬁtted in a similar way using IPT weights, weighting for the
‘missing’ counterfactuals. To simplify, treated patients are weighted with the
inverse probability of being treated and untreated individuals are weighted
with the inverse probability of being untreated. The IPT weight for patient
i at time t can be written
w∗i (t)
=
t∏
k=0
P [A(k) = ai(k)|A¯(k − 1) = a¯i(k − 1), V = vi)]
P [A(k) = ai(k)|A¯(k − 1) = a¯i(k − 1), L¯(k − 1) = l¯i(k − 1)]
.
(4.5)
A MSM could be ﬁtted adjusting for dependent censoring, using the combined
weights wi(t) × w∗i (t).
The idea is that, in the weighted dataset, treatment is independent of the
confounders. The MSM models a situation where treatment is randomized.
The MSM relies on four main assumptions [33]:
1. Consistency. Each individual’s counterfactual outcome under their ob-
served exposure is the same as their observed outcome.
2. Exchangeability. This breaks down to an assumption of no unmeasured
confounders, and is often referred to as the no unmeasured confounders
assumption.
3. Positivity. There must be both exposed and unexposed individuals at
every level of the confounders, so that there are positive probabilities at
all levels. This assumption is sometimes referred to as the experimental
treatment assignment (ETA) assumption.
4. No model misspeciﬁcation. The MSM must be correctly speciﬁed, in-
cluding the probability of treatment and censoring models.
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The assumption of exchangeability (or no unmeasured confounders) is not
testable using observed data, but can be explored with sensitivity analysis [33].
The MSM ﬁtted with IPT weights has both strengths and weaknesses [28],
one of the weaknesses being that the IPT weights can be unstable. If the time
periods, indexed by k in (4.5), are small, the probability in the denominator of
the same equation can be very small, resulting in inordinately large weights
and both bias and imprecision [28]. The problem with instability in IPT
weights is discussed in Paper 3.
4.2.2 Other existing methods
There are alternative methods to the IPT weighting of MSMs for estimating
causal eﬀects for time-varying exposures in the presence of time-dependent
confounders. These methods will give identical eﬀect estimates if certain
requirements are maintained, but in general diﬀerent estimates can be pro-
duced. The estimates will depend on both the causal contrast of interest and
the method’s robustness [28].
One such method is the g-computation [35] of MSMs, also referred to by g-
formula. The g-computation estimation corresponds to maximum likelihood
estimation of MSM parameters [34].
Simpliﬁed, if f(y|do(A = a)) is the distribution of counterfactual or po-
tential outcomes over all individuals, where A is the set of all possible expo-
sure levels a, the causal eﬀect of A on the outcome Y could be evaluated,
given that this distribution was known. However, only the distribution of
outcomes for the actually received exposures is observed, and the eﬀect of
A on Y would be biased when there exists a time-dependent confounder L.
The solution called g-computation is to use the factorization [36]
f(y|do(A = a)) =
∫
l
f(y|do(A = a), L = l)f(l)dl, (4.6)
which corresponds to ordinary standardization when exposure is a ﬁxed base-
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line characteristic, but not when exposure is time-dependent [1]. Under the
assumptions of no unmeasured confounders and consistency, the term in (4.6)
is equal to the observable quantity
∫
l
f(y|A = a, L = l)f(l)dl, (4.7)
which, in simple cases, can be computed directly [28,36].
G-computation of MSMs could be an option when the ETA assumptions
of the IPT weighted MSMs do not hold, and also if it is easier to predict
the outcome given exposure and confounding variables than it is to predict
the exposure given the confounding variables. However, the g-computation
algorithm is often impractical and requires more complicated, iterative pro-
cedures than ﬁtting a MSM using IPT weights [36].
Faced with a choice of modelling the exposure, as in the IPT weighted
MSM, and modelling the outcome, as in the g-computation of MSMs, a third
alternative is to do both, and combine the two approaches. Such methods are
formalized as double robust methods, where the ‘double robust’ term reﬂects
that the method has two ways to discover the correct answer [1]. Such
methods are not discussed any further in this thesis.
Another alternative method is the g-estimation [37] of so-called structural
nested models (SNMs). G-estimation is based on the concept of counterfac-
tual failure times. The idea is that for every individual i, the counterfactual
failure time Ui is the failure time that would have occurred if the individual
was unexposed throughout follow-up. It is then assumed that exposure ac-
celerates the failure time by a factor of exp(−ψ), which is called the causal
survival time ratio. G-estimation is a method for estimating this parameter
ψ [38], and is related to the accelerated life models by Cox and Oakes [1].
Formally, the counterfactual failure time Ui,ψ can be derived from the
observed failure time Ti by
Ui,ψ =
∫ Ti
0
exp(ψei(t))dt, (4.8)
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where ei(t) is 1 if individual i is exposed at time t and 0 otherwise. In
the presence of time-dependent confounding, ψ cannot be estimated using
standard accelerated failure time methods, but it can by using g-estimation.
The key assumption is that there are no unmeasured confounders or, in other
words, that all variables contributing to whether an individual is exposed at
a certain time are measured. If this assumption holds, it means that at each
measurement time the exposure is independent of the counterfactual failure
time Ui. G-estimation is now the search for the value ψ0, for which exposure
at each measurement time is independent of Ui,ψ0 . This could be achieved by
ﬁtting a logistic regression model, modelling exposure by ei(t) with Ui,ψ and
all confounders as covariates. The confounders are then typically the other
covariates at the current time point t, and the values of the other covariates
and exposure at previous time points and baseline. A series of such logistic
regression models are then ﬁtted, with diﬀerent values of ψ. The g-estimate
of ψ, ψ0, is the value of ψ giving a Wald statistic at zero (a p-value of 1) for
the regression coeﬃcient belonging to the Ui,ψ covariate [38]. In the presence
of censoring, g-estimation becomes more complex [1].
The methods discussed in this section so far (IPT weighting of MSMs,
g-computation of MSMs and g-estimation of SNMs) are referred to as g-
methods [28], where the ‘g’ stands for generalized, meaning that g-methods
generally can be used to estimate the eﬀects of time-varying treatments [39].
However, methods for adjusting for confounding in observational stud-
ies can be classiﬁed into two categories: g-methods and stratiﬁcation-based
methods [39]. Stratiﬁcation-based methods include stratiﬁcation, restriction
and matching, and estimating the association between exposure and outcome
in subsets of the population, where the exposed and unexposed are assumed
to be exchangeable [39].
One way to view all these methods is that they try to mimic the situa-
tion of a randomized controlled trial (RCT). The g-methods mimic a RCT
by modelling a situation where the exposure is independent of the confound-
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ing covariates, for example by weighting. Stratiﬁcation-based methods can
mimic a RCT in a more direct sense, by constructing subsets of the pop-
ulation where exposed and unexposed can be compared without bias. The
method discussed in the next subsection, and in Paper 3, is a method based
on mimicking RCTs by manipulating the observed data.
4.2.3 The sequential Cox method
We still consider estimating the causal eﬀect of an exposure in the presence
of time-dependent confounders using observational data. Say that the ex-
posure variable is a dichotomous treatment variable where, once treatment
is initiated, individuals by deﬁnition do not return to being untreated. The
sequential Cox method [40] is based on mimicking a sequence of RCTs, each
of which can be analysed using a standard Cox proportional hazards model,
and then combining these analyses using composite likelihood inference [41].
The method is presented formally in Paper 3.
Each of the mimicked RCTs when using the sequential Cox method are
constructed based on individuals starting treatment in a certain time interval
k, called the reference interval. If the measurement scale in such data is
months since inclusion in the study, each observation month could deﬁne
such a time interval, but there are also other intervals that could be used.
The individuals initiating treatment in time interval k form the treat-
ment group in the mimicked trial, while the individuals not yet on treatment
by interval k form the control group. However, the individuals not yet on
treatment by interval k are artiﬁcially censored from the mimicked trial if
they start treatment at a later time point (in an interval > k). Then, in the
Cox proportional hazards analysis of one such mimicked trial, baseline co-
variates and covariate values at time interval k would typically be controlled
for. Time-dependent confounding variables would be aﬀected by exposure,
and are thus not included. Only covariate values at baseline and at the ‘local
baseline’ in the mimicked trial (covariate values at interval k) are included.
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If there is bias due to dependent censoring, this could be adjusted for using
IPC weights, along with the dependent censoring introduced by the artiﬁcial
censoring needed to construct the mimicked trials. Including such weights,
the estimated parameter in a weighted Cox model would have a causal in-
terpretation if:
1. there are no unmeasured confounders,
2. the model for estimating the hazard rate is correct, and
3. the model for estimating the censor weight is correct.
The idea is now to construct such mimicked RCTs for every possible ref-
erence interval k. Say there are K such trials to mimic. The partial score
functions from each of the K mimicked trials can be combined using com-
posite likelihood techniques [41] to estimate an overall eﬀect of treatment.
See Paper 3 for details. This overall estimate will still have a causal inter-
pretation given the assumptions that:
1. the treatment eﬀect is the same in every trial, and
2. the eﬀect of treatment is the same for all covariate histories before the
reference interval k, given covariates at interval k.
However, the ﬁrst of these two assumptions can be relaxed by interpreting
the overall eﬀect estimate as an average or aggregated causal eﬀect over all
mimicked trials. Using the composite likelihood to combine the analyses is
similar to taking a weighted average.
As for the other methods, the sequential Cox method has advantages and
disadvantages. One advantage compared to the IPT weighted MSM is that
the problem of unstable IPT weights is avoided (see Paper 3 for further
discussion). Another advantage is that possibilities open up due to the con-
ditioning on covariate values at time k; this makes it possible to investigate
treatment eﬀects for diﬀerent covariate values at the time of treatment start.
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A third advantage is that the model is easy to implement using standard
methods and software once you have constructed a dataset for each of the
K mimicked trials. Then the overall eﬀect estimate could be estimated us-
ing a stratiﬁed weighted Cox model, stratiﬁed on k. A disadvantage is that
you could end up creating a very large pseudo dataset, consisting of data
for all the K constructed trials. Also, the conﬁdence intervals based on the
Wald statistics would not be valid, and using bootstrap methods can be time
consuming.
5 Direct and indirect eﬀects
The concepts of direct and indirect eﬀects are connected to a mechanistic
view of causality [2]. The idea is that the eﬀect of treatment can be divided
into a direct eﬀect and an indirect eﬀect. An indirect eﬀect is the eﬀect
of treatment going through some intermediate variable. Depending on the
situation, there can be many such indirect eﬀects of one treatment going
through diﬀerent intermediate variables. The direct eﬀect is the remaining
eﬀect not mediated through any of these intermediate outcomes.
Path analysis is a method for estimating such direct and indirect eﬀects
for a set of variables, using a pre-speciﬁed system of causal relationships.
These relationships between variables are usually represented in a path dia-
gram, which we will describe further in Section 5.1.2. Path analysis was orig-
inally developed by geneticist Sewall Wright in the 1920s [42, 43]. Decades
later, in the 1950s and 1960s, it was introduced in economics and sociology.
During the 1970s it grew more popular and emerged in numerous papers in
ﬁelds such as psychology, political science, ecology and others [44], and it
was generalized into structural equation modelling (SEM).
Since it was introduced, path analysis has been subject to criticism and
debate considering the value of the method, especially with regard to causal-
ity. When Wright used the word ‘causal’ in connection with his ﬁrst path
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models, it started a furious debate with Henry Niles [45], even though he
urged people to be cautious about the use. Many of the criticisms by Niles,
and the responses to them, have been repeated in the modern discussion of
path analysis and SEM. Most of the criticism is related to cases where there
is insuﬃcient information to specify causal relations and where the usefulness
of applying the model is unclear [46].
More recently, in relation with to growing causal movement in statis-
tics, there has been new attempts to handle many of these problems using
counterfactual frameworks, structural model frameworks, graphical methods
and combinations of these. Authors such as Robins [37, 49], Greenland [48],
Pearl [50], Rubin [51], van der Lan [52] and many others have developed
methods for the identiﬁcation of direct and indirect eﬀects [47].
It is also being argued that when the goal is to understand underlying
mechanisms, it is natural to think in less deﬁnite terms than tends to be
the case for statistical causal inference. Here, causality is usually viewed
as absolute; either the eﬀect is causal, or it is only an apparent eﬀect due
to confounding or bias [2]. Even in cases where the information on causal
relations is insuﬃcient and the usefulness of the model unclear, a speciﬁed
model could still be used to explore relations that will be tested in subsequent
studies [46].
When discussing direct and indirect eﬀects in the remainder of this thesis,
the focus will mainly be on topics related to the dynamic path analysis of
Paper 4. However, there will also be given a short introduction to graphical
models, such as causal directed acyclic graphs and path diagrams, which are
related topics when estimating such eﬀects. To read more on classical path
analysis, SEM and direct and indirect eﬀects in general, see the references
given above or Pearl [20].
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5.1 Graphical models
A graphical model is a statistical or probabilistic model where dependencies
between random variables are represented by means of a graph [53]. Graph-
ical models in statistics is a huge ﬁeld, including wide classes of models such
as Bayesian networks, Markov networks and others. The topics in this sec-
tion will be limited to two speciﬁc types of graphical models, namely causal
directed acyclic graphs and dynamic path diagrams. These types of graphical
models are used in Paper 3 and Paper 4 in this thesis. For other methods,
see for example Lauritzen [54].
5.1.1 Causal directed acyclic graphs
Much of the theory around graphical models in causality was presented by
Judea Pearl in his book from 2000 [20]. Most of these models are based on
the use of directed acyclic graphs (DAGs). Often, statements in the counter-
factual or potential outcome framework can be represented concisely using
graphs, and Pearl also showed that many fundamental concepts in the two
diﬀerent frameworks were equivalent. It was shown that such graphical mod-
els provide a direct and powerful way of thinking about causal systems and
that identiﬁcation strategies could be used to estimate eﬀects within such
systems [21]. In the following section there will be a short introduction to
some of these concepts, starting with some graph terminology [1, 20].
A graph is a set V of vertices or nodes and a set E of edges. The nodes
usually represent random variables, while the edges, which are links or the
arrows in the graph, are connections between the nodes. An edge between
two variables indicates a certain relationship between them. An example of
a graph is given in Figure 3.
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Figure 3: A graph with four nodes X, Y , Z and Y .
An edge could be undirected, like the edge (X, Y ), directed, like the edges
(U, Y ) and (Y, Z), or bidirected like the edge (X,U) [20]. If all edges are
directed, the graph is called a directed graph. A path in a graph is a sequence
of edges connected to each other, such as ((Y,X), (X,U), (U, Y ), (Y, Z)) in
Figure 3. This is regardless of the direction of the edges. A directed path
is a special case where all the edges are directed from the starting node to
the end node. Any other path is an undirected path. If there exists a path
between two nodes, these nodes are said to be connected, otherwise they are
disconnected. A cyclic graph is a graph where there exists at least one path
going out of a node which can be followed through directed edges back to the
original node. An acyclic graph is a graph that contains no such cycles. So,
a directed acyclic graph (DAG), is a graph that is both directed and acyclic,
such as the graph in Figure 4.

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Figure 4: A direct acyclic graph (DAG).
A node, or variable, where two arrowheads meet, such as Y in Figure 4, is
called a collider. The children of a variable are the variables that are aﬀected
directly by that variable. For example, Y is a child of both the variables X
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and U , and Z is a child of Y . Correspondingly, parents of a variable are
the variables directly aﬀecting that variable; X and U are the parents of Y .
Generally, variables aﬀecting another variable, directly or indirectly through
a certain path, are called ancestors, while variables being aﬀected, directly
or indirectly, are called descendants. A node, or variable, without parents is
called exogenous, otherwise it is endogenous.
A causal DAG is a DAG where the arrows can be interpreted as causal
relationships and where all common causes of any pair of variables in the
graph are included [55].
Generally, as listed in [1], four diﬀerent causal structures can contribute to
the association between two variables X and Y : 1) X causes Y , 2) Y causes
X, 3) X and Y share a common cause which has not been conditioned on
(confounding), or 4) it has been conditioned or selected on a variable which
is aﬀected by X and Y , on a variable which is inﬂuenced by such a variable,
or on a variable sharing causes with X and Y (collider bias).
Besides giving a visual representation of a causal system, the methodology
around causal DAGs is a powerful tool for identifying causal relations and
for recognizing and avoiding common mistakes in causal analysis. One such
important tool is d-separation, or directed graph separation. Here, a path is
called open or unblocked if it has no colliders along it. If there is a collider
on the path, it is called closed or blocked. Two variables are said to be d-
separated if there is not an open path between them, and otherwise they are
said to be d-connected. If two variables are d-separated, it implies that they
are marginally independent [1].
There is also a concept of graphical conditioning, called conditional d-
separation, which can be summarized by the following rules: 1) to condition
on a non-collider Z on a path blocks the path at Z, and 2) to condition on
a collider W , or a descendant of W , opens the path at W .
There are also other concepts. An undirected path from X to Y is called
a back-door path if it starts with an arrow pointing into X. To identify the
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causal eﬀect of X on Y , all back-door paths must be blocked. A set of
variables S is said to satisfy the back-door criterion for identifying the eﬀect
of X on Y if it contains no descendants of X and there are no open back-door
paths from X to Y when conditioning on S.
To read more about these and related methods see Pearl [20] and Roth-
man, Greenland and Lash [1]. Some of the concepts discussed in this section
are used in Paper 3.
5.1.2 Path diagrams
In path analysis, or more generally in SEM, a path diagram is a graphical
representation of the model in question. The diagram is equivalent to a set
of equations deﬁning this model (in addition to distributional assumptions)
[56]. Unlike the DAGs, dynamic path diagrams could have bidirected arrows,
representing correlation between variables. For more on path diagrams for
SEM, see for example Raykov and Marcoulides [56] and Spirtes et al. [57].
A dynamic path diagram is a version of the regular path diagram, which
illustrates dependencies for time-dependent variables. It can be viewed as a
set of time-indexed DAGs for all t ∈ [0,∞) [58]. An example of a dynamic
path diagram can be seen in Figure 5 [2]. Here, A is a ﬁxed covariate, for
example a treatment indicator, and L(t) is a time-dependent covariate. dD(t)
is the increment of some event of interest, measured by some counting variable
D(t), for example death. α1(t), β1(t) and β2(t) are the path coeﬃcients,
where, for example, β2(t) describes the eﬀect of the covariate L on dD at
time t.
The use of dynamic path diagrams is related to the method of dynamic
path analysis, which is the topic in the next subsection and in Paper 4. For
more on dynamic path diagrams, see Fosen et al. [58].
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Figure 5: A dynamic path diagram with three nodes, A, L(t) and dD(t), path
coeﬃcients α1(t), β1(t) and β2(t).
5.2 Dynamic path analysis
In path analysis the aim is to estimate the path coeﬃcients from a path
diagram, analogous to the path coeﬃcients in the dynamic path diagram in
Figure 5. The main assumption is that each variable is a linear combination
of all the parents in the path diagram. Estimating the path coeﬃcients
in a regular path analysis would correspond to ﬁtting a number of linear
regression models, regressing each variable or node in the graph onto all of
its parents. The eﬀect belonging to a certain path in the graph, from one
variable to the outcome variable of interest, such as the indirect eﬀects, is
found as the product of all the estimated path coeﬃcients along that path.
The total eﬀect can be found as the marginal eﬀect on the outcome, but
additivity also provides that the sum of the direct eﬀect and the indirect
eﬀects add up to the total eﬀect. To read more about regular path analysis
and SEM in general, see for example John C. Loehlin [59].
Dynamic path analysis is a generalization of regular path analysis; it is
a combination of path analysis and Aalen’s additive regression model [2].
Dynamic path analysis is carried out using recursive least squares regression,
as in regular path analysis. Each node in the dynamic path diagram is
regressed onto its parent for each time t. The set of variables can be divided
into a covariate set (L1(t), L2(t), ..., Lp(t)) and an outcome. In contrast to
regular path analysis, the outcome in dynamic path analysis is an outcome
process dD(t). See the dynamic path diagram in Figure 5. In dynamic path
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analysis, the covariates can be both ﬁxed and time-dependent. The path
coeﬃcients going into the node of the outcome process are estimated using
the additive regression model, with the outcome process as the dependent
variable and its parent variables as covariates.
Analogous to regular path analysis, the eﬀect attributable to a certain
path at time t in the dynamic path diagram can be calculated as the product
of all the path coeﬃcients belonging to that particular path at time t. This
is done for all possible times t, and the direct and indirect eﬀects are plotted
against time, as the time-dependent eﬀect or regression function itself, or as
cumulative eﬀects. Using the example in Figure 5, the direct eﬀect of A is
β1(t), while the indirect eﬀect of A is the eﬀect α1(t)β2(t), going through
L(t). Again, the total eﬀect is found as the marginal eﬀect, and also the sum
of the direct and the indirect eﬀects.
Dynamic path analysis still has some limitations, discussed for example
by Martinussen [60]. The most important reason to be cautious when in-
terpreting estimates of direct and indirect eﬀects is the possible bias due
to unmeasured confounders. This poses an even bigger problem when es-
timating such eﬀects than when estimating marginal or total eﬀects. With
the latter, for the estimate to be unbiased, there should be no unmeasured
confounders between treatment and the outcome. When estimating direct
and indirect eﬀects, there should in addition be no unmeasured confounders
between the mediator and the outcome. See Figure 6 for an illustration of
such an unmeasured confounder U(t) in the dynamic path diagram from
Section 5.1.2. Assumptions of no unmeasured confounders are in general not
testable, and will be even more diﬃcult to control in more advanced path
models than in the regular regression framework.
Despite the reservations, dynamic path analysis is a useful tool for better
understanding how the eﬀect of a treatment on a time-to-event endpoint
is mediated through time-dependent covariates [60]. See Paper 4 for a
further discussion on these topics. For more detailed reading on dynamic path
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Figure 6: A dynamic path diagram showing a possible unmeasured confounder
U(t).
analysis, see especially Fosen et al. [58], Aalen et al. [2] and Martinussen [60].
5.2.1 Composite dynamic path analysis
In Paper 4 we discuss a situation where it is reasonable to be interested
in direct and indirect eﬀects, or path coeﬃcients for that matter, averaged
over many dynamic path analyses. Such analyses could be the dynamic path
analyses of multiple mimicked RCTs, such as the ones being constructed
using the sequential Cox method in Section 4.2.3 and in Paper 3.
Multiple dynamic path analyses can be combined by aggregating over
their estimating equations, which corresponds to the composite likelihood
inference [41] used in Section 4.2.3 or, more loosely speaking, to a kind
of weighted averaging over the diﬀerent analyses. To estimate aggregated
path coeﬃcients, both such composite linear regression models and compos-
ite additive regression models have to be ﬁtted. Using artiﬁcially censored
datasets such as the mimicked randomized trials from Section 4.2.3 and Pa-
per 3, dynamic path analysis is generalized into composite weighted dynamic
path analysis [61]. See Paper 4 for more details on both aggregating and
weighting dynamic path analysis models.
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6 Summary of the papers
The current section gives a brief summary of the four papers that form this
thesis.
6.1 Paper 1: ‘Growth rates in epidemic models: Ap-
plication to a model for HIV/AIDS progression’
In this paper we discuss the use of epidemic growth rates and reproduction
numbers, with application to compartment models for infectious diseases.
The compartment model used to illustrate the methods is a generalized SIR
model for HIV/AIDS progression, based on a Markov model in an earlier
paper by Aalen et al. [18].
We discuss the use of these diﬀerent reproduction numbers and growth
rates, such as the basic reproduction number R0, the eﬀective reproduction
number Re(t), the actual reproduction number Ra(t) and the intrinsic growth
rate r. We also discuss the relationship between them, study their behav-
ior using our HIV/AIDS progression model and brieﬂy discuss how these
quantities can be estimated from observed data.
The main aim of the paper, beside summarizing the diﬀerent reproduction
numbers and growth rates, is to communicate that, apart from the basic
reproduction number R0 (the predominant quantity), many other measures
of epidemic growth will give important supplementary information, and in
some situations be more relevant than R0.
6.2 Paper 2: ‘ Estimating inﬂuenza-related excess mor-
tality and reproduction numbers for seasonal in-
ﬂuenza in Norway, 1975–2004’
The main aim of this paper is to estimate the mortality attributable to sea-
sonal inﬂuenza in Norway, using surveillance data on inﬂuenza-like illness
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(ILI) and data on overall mortality. Such data is available from the Nor-
wegian Notiﬁcation System for Infectious Disease and the Cause of Death
Register at the Norwegian Institute of Public Health. Even though most
inﬂuenza patients make a full recovery, it can be a deadly disease for the el-
derly and patient groups with certain underlying severe diseases. Therefore,
measuring the impact of inﬂuenza on mortality is an important public health
priority.
In addition to the estimation of excess mortality, we also study the esti-
mation of reproduction numbers. This work can be seen as an addition to
the work on reproduction numbers and growth rates in Paper 1. In the
paper we discuss methodological diﬀerences in existing methods for estimat-
ing excess mortality, used on data from other countries, before we estimate
the excess mortality in Norway from 1975 to 2004 using a Poisson regression
based model. Excess mortality is estimated for the overall population and
for diﬀerent age groups.
We estimate overall inﬂuenza-related excess mortality in Norway to be an
average of 910 deaths per season, or 2.08% of overall deaths. Age-grouped
analyses indicate that the major excess mortality is among the elderly in the
population. Estimates of the reproduction numbers for the diﬀerent seasons
range from about 1.00 in seasons with no signiﬁcant outbreak to 1.69.
6.3 Paper 3: ‘A sequential Cox approach for estimat-
ing the causal eﬀect of treatment in the presence of
time-dependent confounding applied to data from
the Swiss HIV Cohort study’
In this paper we discuss the estimation of the causal eﬀect of treatment from
observational data, in the presence of time-dependent confounding. As in
Paper 1, the focus is on HIV/AIDS, here using data from the Swiss HIV
Cohort Study.
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We introduce a method based on mimicking a sequence of randomized
controlled trials, and analyse them together using Cox regression and com-
posite likelihood inference. We compare our method to the MSM ﬁtted using
IPT weights, which is perhaps the most established method for controlling
for such time-dependent confounding.
We show how the sequential Cox method introduced in this paper avoids
the use of IPT weights and the instability problems associated with the use of
such weights in a MSM. We discuss the diﬀerences between the two models,
the parameter being estimated, and how these diﬀerences lead to diﬀerent
possibilities when it comes to estimation. We also see that when estimating
the overall eﬀect of HIV treatment on data from the Swiss HIV Cohort Study,
both the sequential Cox method and the IPT ﬁtted MSM give similar results.
6.4 Paper 4: ‘Analysing direct and indirect eﬀects of
treatment using dynamic path analysis applied to
data from the Swiss HIV Cohort Study’
In this paper the aim is to estimate direct and indirect eﬀects of treatment
for HIV using dynamic path analysis. As in Paper 3, the application is to
data from the Swiss HIV Cohort Study.
As in the previous paper, we construct and analyse mimicked randomized
trials from the original data. We extend regular dynamic path analysis to
include censor weighting and deﬁne composite estimates of direct and indirect
eﬀects, combining all the mimicked trials.
We show that even simple dynamic path models, with one mediating
variable such as the HIV-1 RNA or CD4 level, serve as a useful tool to
investigate underlying processes that are often ignored when estimating total
treatment eﬀects. The results when applying these models to the Swiss data
show that most of the treatment eﬀect goes through the RNA level for the
ﬁrst three or four years after starting treatment. Using CD4 instead of RNA
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as the intermediate variable results in a smaller estimate of the indirect eﬀect.
We also discuss the limitations of such methods, and the need for caution
when interpreting estimates of direct and indirect eﬀects, for example with
regard to possibly unmeasured confounders.
7 Discussion
The work in this thesis covers two main areas: infectious disease modelling
and causal inference. This division is most apparent between the ﬁrst two
and last two papers. However, setting this distinction aside, there are many
other aspects binding these four papers together, some of which were men-
tioned in the introduction. Common to all papers is that they deal with
infectious diseases. Paper 1, Paper 3 and Paper 4 are all applied in a
HIV/AIDS setting, while Paper 2 is applied to inﬂuenza data. Studies of
infectious disease are closely linked with understanding mechanisms. State-
ments therefore tend to be more causal than in studies of chronic diseases.
For example, when estimating the eﬀect of some countermeasure that modi-
ﬁes the transmission rates in a multi-stage model such as the one in Paper 1,
the goal is in fact to estimate the causal eﬀect of that countermeasure, similar
to the causal eﬀect of treatment estimated in Paper 3. Even in Paper 2,
when using the inﬂuenza level in one week to model the number of deaths a
week later, the fact that one event precedes the other indicates that a certain
mechanism is assumed. The similar way of thinking about mechanisms in
infectious diseases and in causality is also evident through the use of com-
partment or network models in infectious disease modelling and path models
and graphs in causal inference. Consider for example the compartment model
in Paper 1 and the dynamic path models in Paper 4.
The main contribution of Paper 1 is the summary of the diﬀerent growth
rates and reproduction numbers for describing epidemic growth, and the
study of how these growth rates behave and relate to each other. Another
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contribution is the model for HIV/AIDS disease progression, as a generalized
SIR model and an extension of previously used Markov models. Possible
future extensions of this work would be to adjust the model to the situation
now being seen after the introduction of HAART treatment. Early attempts
on this can be seen in Aalen et al. [14], but that was just three years after
HAART was introduced. Also, in connection to causal inference, a future
extension could be to study the use of this kind of transition models in
estimating treatment eﬀects.
As for Paper 2, the main contribution is the estimates of inﬂuenza-
related excess mortality in Norway between 1975 and 2004, both overall
and within age groups. Estimates of such numbers are of interest to public
health representatives, such as the Norwegian Institute of Public Health,
and to others working with decision-making and in related areas. Another
contribution in this paper is the estimation of growth rates and reproduction
numbers for the same data, as few estimates from seasonal inﬂuenza are
available in the literature. Possible extensions to the work in this paper
would be to compare the methods used with other methods for estimating
excess mortality, and to make more detailed models based on geographical
data, which could make it easier to include other relevant covariates such
as temperature. Data for the years between 2004 and 2010 are also now
available to be studied.
The main contribution of Paper 3 is the introduction of a new approach
for estimating causal eﬀects of treatment from observational studies, com-
bining the ideas of mimicking randomized trials and composite likelihood
inference. Using data from the Swiss HIV Cohort Study, we show results
similar to the ones using a MSM, and that the method can be implemented
using existing methods when a manipulated version of the original dataset
is created. Possible extensions to this work would be to study the method
more systematically, for example using simulation studies.
In Paper 4, the main contribution is the extension of dynamic path
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analysis, introducing both weighting and composite analysis, to analyze the
same type of observational data as used in the previous paper. Possible future
work would be to study how and when models with more complex covariate
dependencies can be used, and also to address the remaining challenges in
formalizing the method of dynamic path analysis in general.
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SUMMARY
Inﬂuenza can be a serious, sometimes deadly, disease, especially for people in high-risk groups
such as the elderly and patients with underlying, severe disease. In this paper we estimated the
inﬂuenza-related excess mortality in Norway for 1975–2004, comparing it with dominant virus
types and estimates of the reproduction number. Analysis was done using Poisson regression,
explaining the weekly all-cause mortality by rates of reported inﬂuenza-like illness, together with
markers for seasonal and year-to-year variation. The estimated excess mortality was the
diﬀerence between the observed and predicted mortality, removing the inﬂuenza contribution
from the prediction. We estimated the overall inﬂuenza-related excess mortality as 910 deaths per
season, or 2.08% of the overall deaths. Age-grouped analyses indicated that the major part of the
excess mortality occurred in theo65 years age group, but that there was also a signiﬁcant
contribution to mortality in the 0–4 years age group. Estimates of the reproduction number R,
ranged from about 1 to 1.69.
Key words : Excess mortality, inﬂuenza (seasonal), reproduction numbers.
INTRODUCTION
Inﬂuenza is an infection of the respiratory tract
caused by the inﬂuenza viruses ; RNA viruses be-
longing to the family Orthomyxoviridae [1]. The dis-
ease is characterized by acute-onset fever, headache,
myalgia, prostration, coryza, and a dry cough, and is
usually self-limiting with recovery in 2–7 days [2, 3].
Primary viral, or secondary bacterial pneumonias are
common complications of inﬂuenza. Most inﬂuenza
patients recover without sequelae. Mortality is highest
in the elderly and in patient groups with certain
underlying, severe diseases [1–3]. For these risk
groups annual inﬂuenza immunization is rec-
ommended in many countries.
In the northern hemisphere the virus usually
causes annual outbreaks of varying length and
severity during the winter seasons. When a new virus
variant emerges to which no one is immune, larger
epidemics – know as pandemics – may ensue. Last
century three worldwide pandemics occurred; in
1918–1919 (Spanish ﬂu), 1957–1958 (Asian ﬂu), and
1968–1970 (Hong Kong ﬂu) [2, 4].
Most developed countries have some sort of sur-
veillance system for inﬂuenza measuring the number
of patients seeking healthcare, virologically conﬁrmed
cases or some other marker for inﬂuenza-like illness
(ILI) such as absence from school or work. No
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country has routine surveillance of inﬂuenza-related
deaths.
It is diﬃcult to discern if the cause of death is
from inﬂuenza in patients with several other serious
underlying illnesses. Inﬂuenza is rarely recorded as
the cause of death on death certiﬁcates in Norway.
Internationally many studies have been performed
to estimate the mortality due to inﬂuenza [5–15],
in Norway this has only been done for inﬂuenza
pandemics [16].
The aim of this work was to estimate the excess
mortality due to inﬂuenza in Norway by studying the
relationship between the number of reported deaths
and clinical inﬂuenza activity ; and to compare these
results with information on predominant inﬂuenza
viruses and estimates of the reproduction number, R,
for the diﬀerent seasons.
METHODS
Data material
Information on clinical ILI was derived from
The Norwegian Notiﬁcation System for Infectious
Diseases (MSIS). For the period 1975–1998 all gen-
eral practices in primary healthcare and outpatient
emergency clinics were obliged to report ILI along
with other clinical diagnoses on a weekly basis to the
Norwegian Institute of Public Health (NIPH). The
average reporting coverage was about 60% of around
2000 practices. Rates of ILI were calculated as a
proportion of the total population, without adjusting
for the reporting coverage.
From autumn 1998 NIPH designated 201 sentinel
reporting units based on geographical location,
population size and previous reporting frequencies
from the 2000 practices mentioned above. These
formed about 10% of the practices but about 25% of
the reported volume of ILI. The sentinels reported
weekly, from week 40 in autumn to week 20 in spring,
the number of ILI [using the case deﬁnition of ‘R80
Inﬂuenza’ from the International Classiﬁcation of
Primary Care (ICPC)]. The number of consultations
and, from 2004–2005 when the information was
available, the number of patients on the patient list of
general practitioners, were used as denominators.
The weekly recording period was from Friday to
Thursday, after which the report card was completed
and sent to NIPH by post and entered into a database
in EpiInfo 6.04d (CDC, USA). Quality checks for in-
consistencies and improbable ﬁgures were performed.
Data on all-cause mortality per week by age group
were derived from the Cause of Death Register at
NIPH. The week number was obtained by deﬁning
week 1 as starting on 1 January each year, week 2 on
8 January and so on. Hence there may be a small
discrepancy between the week numbering of ILI and
deaths.
Information about dominant virus types and
variants for each season was obtained from the vi-
rological inﬂuenza surveillance records in the Depart-
ment of Virology, NIPH.
Estimating excess mortality
The number of overall deaths per week was modelled
using a Poisson regression model, where the mortality
rate was explained by the reported number of ILI
cases, the week number and the season. For the ILI
covariate, we considered diﬀerent lagging, before
choosing the type of lag which gave the best model ﬁt
(i.e. explained the most variability). The week number
covariate, a factor numbered between 1 and 52,
modelled the seasonality in the data, while the season
covariate was a substitute for calendar year. Season
was used instead of calendar year because a normal
inﬂuenza season goes from autumn of one year to
spring of the next.
To account for change in population size, the
Norwegian population size at the beginning of each
calendar year was used as an oﬀset. The model is
written as:
D^j, k= exp ( log (Populationj, k)+b0+bILI
rILIj, k+bweekj+bseasonk),
where Dˆj,k is the predicted number of overall deaths
in week number j and season k, js{1, 2, …, 52}, and
ks{spring 1975, 1975/1976, 1976/1977, …, 2003/
2004, autumn 2004}. Populationj,k is the total popu-
lation size of Norway on 1 January for the year
containing week j in season k, b0 is the intercept co-
eﬃcient, bILI the coeﬃcient to the ILI contribution
(ILIj,k being the reported number of ILI cases in week
j in season k), bweekj the coeﬃcient for the factor
variable week at week j, and ﬁnally bseasonk , the co-
eﬃcient associated with season k. To account for any
extra Poisson variation, a dispersion parameter was
added, making the model a quasi-Poisson model. The
analysis used the GLM package in the open source
statistical software R version 2.7.0 [17].
The model was ﬁtted separately for the two data-
sets, one going from 1975 to 1998, the other from 1998
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to 2004. The only weeks included in the analysis were
the observed weeks and weeks where the ILI levels
with the chosen lag were available. For the data from
1998 to 2004, no ILI ﬁgures were collected oﬀ-season,
i.e. between week 20 and week 40.
The excess mortality was estimated by ﬁrst con-
sidering the overall mortality once the inﬂuenza
contribution had been removed. Rather than setting
the inﬂuenza contribution to zero in this estimation,
leaving the other parameters and covariates as they
were, the inﬂuenza contribution was set to some
threshold value accounting for the ever-present base-
line of ILI cases, also observed oﬀ-season. As pre-
viously mentioned, oﬀ-season ILI numbers were not
collected in the new reporting system, and one would
expect these weeks (if measured) to represent the
lowest ILI counts. We therefore removed the corre-
sponding number of high ILI values, and then most of
the outbreaks, to ﬁnd this threshold. In other words,
the threshold value was set to the mean of the re-
maining ILI values, excluding the 20 lowest and 20
highest values for each season. We expected this to
give a conservative estimate of the oﬀ-season ILI
level. The estimated excess mortality related to ILI
was then calculated as the diﬀerence between the ob-
served mortality and the predicted mortality leaving
out the inﬂuenza contribution above this threshold.
Estimating the reproduction number
The reproduction number R, also known as the
eﬀective reproduction number, denotes the number of
secondary infections caused on average by one in-
fected individual being introduced into a population.
R relates to R0, the reproduction number for an
individual introduced into a population of only
susceptibles. R0 serves as a threshold value for epi-
demic growth, where R0=1 is the threshold deciding
whether an epidemic is possible or not [18, 19]. When
a fraction p of a population is protected from infec-
tion, the relationship between R and R0 is given by
R=(1xp)R0 [20, 21].
The reproduction number can be estimated through
the initial growth rate of an epidemic r [18, 19, 21],
which describes the growth of the epidemic in its
initial phase, rather than the individual reproduction
as with R.
When the initial growth of an epidemic is assumed
to be exponential, r can be estimated by ﬁtting a
straight line to the natural logarithm of the number of
infected individuals at each time point in the initial
phase. The slope of this line is then the estimated
initial growth rate r.
To determine the initial phase of an epidemic is a
challenge, but one method is to consider the goodness
of ﬁt [20, 22]. We determined the initial phase by
ﬁnding the starting point and the endpoint separately.
The starting point was found by looking for structural
change when modelling the natural logarithm of the
number of infected individuals with linear regression,
using data from the start of each season until the time
of the inﬂuenza peak. If there was an inﬂuenza out-
break during this period, a breakpoint on the log scale
of the ILI curve should exist. The breakpoint was
found using the methods described in Zeileis et al. [23]
(implemented in the R package STRUCCHANGE). These
methods test the null hypothesis of no change in
regression parameters before and after each possible
time point, and then choose the time point giving the
lowest P value as the breakpoint, if this is signiﬁcant.
The endpoint, restricted to be at least three points
later than the start point and no later than the peak,
was chosen by the best goodness of ﬁt in terms of R2.
Using the estimate of r we were able, by assuming a
simple multistage model for the disease spread, to
derive an expression for the reproduction number R
[21, 24, 25]. Assuming a SEIR model (susceptible,
exposed, infectious, recovered) for the spread of
inﬂuenza, we obtained
R=1+
r2+(k+c)r
kc
,
where kx1 is the incubation time and cx1 the infec-
tious period [24]. When calculating the R estimates for
seasonal inﬂuenza we assumed a 2-day incubation
time and a 4-day infectious period [20, 26]. A 95%
conﬁdence interval (CI) for the estimate of R was
found using the lower and upper conﬁdence limits for
the estimate of r (derived from the linear regression
model), and the formula for R above.
RESULTS
In the Poisson regression analysis, applying a lag of 1
week to the ILI variable gave the best model ﬁt, when
also adjusting for week and season variables. Figure 1
shows an overview of the data on ILI and all-cause
mortality as used in the analysis.
The estimated excess mortality for season 1975/
1976 to season 2003/2004 varied from 217 deaths
(5.31/100 000 population or 0.53% of all deaths) in
the 1976/1977 season, to 1802 deaths (41.45/100 000
Seasonal inﬂuenza in Norway 1561
population or 3.89% of all deaths) in the 1993/1994
season: this gave a mean estimated excess mortality of
910 deaths per season (21.25/100 000 population or
2.08% of all deaths), ignoring the two incomplete
seasons of spring 1975 and autumn 2004.
Figure 2 shows the observed, overall deaths
per week, the overall deaths per week modelled
by Poisson regression, and the predicted mortality
leaving the inﬂuenza contribution ﬁxed at the deﬁned
threshold value, under both the old and new reporting
systems. The threshold value was found to be 45.91/
100 000 population in the data from the old reporting
system, and 0.54/100 consultations for the data from
the new reporting system. The agreement between
the observed mortality and the predicted mortality
suggests a good model ﬁt. The estimated dispersion
parameters in the analysis of the two datasets were
1.85 and 2.23, respectively. In Figure 2 the estimated
excess mortality is the area between the line of the
predicted mortality, where the inﬂuenza contribution
is limited to the threshold value, and the line of the
observed mortality (this is most visible in the lower
panel).
The estimated excess mortality for each inﬂuenza
season from 1975/1976 to 2003/2004 is listed in
Table 1. This table also gives the total number of ILI
cases/100 000 population for the old dataset, the mean
number of ILI cases/100 consultations for the new
dataset, estimates of R with 95% CIs and dominant
virus type for each season. The R estimates range
from close to 1, implying no outbreak, to 1.69 in the
1999/2000 season.
In Figure 3 we plotted the estimated excess mor-
tality against estimates of R for each season, marked
by groups of dominant virus type. It can be seen that
inﬂuenza B seasons tended to have lower estimated
excess mortality and R estimates than H3N2 seasons.
For the other seasons, it can be seen that the two
H1N1 seasons both had low estimates of excess mor-
tality and R. Seasons with more than one dominant
virus had varying estimates of excess mortality and R,
while seasons with no dominant virus had low esti-
mates. The mean estimated excess mortality in H3N2
seasons was 1169 deaths per season, compared to a
mean estimated excess mortality of 781 deaths per
season in B seasons. The mean estimated excess mor-
tality in H1N1 seasons was 425 deaths per season, but
there were only two seasons with H1N1 as the single
dominant virus type. When testing the mean diﬀer-
ence between estimated excess mortality in H3N2 and
B seasons, using a standard two-sample t test, we
found that the diﬀerence was signiﬁcant at a 5% level
(P value=0.01). When we did a similar test on the
mean diﬀerence between estimated R in H3N2 and
B seasons, again we found a signiﬁcant diﬀerence
(P value=0.00002).
Table 2 shows estimates of bILI together with esti-
mated excess mortality, for overall and age-grouped
analyses. For the dataset going from 1975 to 1998 the
level of ILI had a signiﬁcant eﬀect on the overall
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Fig. 1. Overall deaths per week (grey line) and reported number of inﬂuenza-like illness (ILI) cases the week before (black
line), from the old (upper panel) and new (lower panel) reporting system.
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deaths in all ages except 5–14 years (using a 5% level
of signiﬁcance). It can also be seen that the highest
(signiﬁcant) eﬀect is in the o65 years age group, fol-
lowed by the 0–4 and 15–64 years age groups. Most of
the estimated excess mortality was found in the o65
years age group. Considering the data going from
1998 to 2004 we saw the same patterns, but here the
level of ILI had no signiﬁcant eﬀect on the overall
mortality in either the 5–14 or 15–64 years age groups.
The eﬀect was higher in the 0–4 years group than in
the o65 years group, but almost all the excess mor-
tality was in the oldest group. Note that the estimated
bILI values for 1975–1998 and 1998–2004 cannot be
compared to each other because of the diﬀerent units
for ILI level in the two periods.
DISCUSSION
Our model seems to give a good description of the
observed mortality, capturing both the season-to-
season change in the number of ILI cases, and the
severity. This is also reﬂected when investigating esti-
mates of the reproduction number R and dominant
virus types for the diﬀerent seasons. The H3N2
seasons had a signiﬁcantly higher excess mortality and
R estimates than the inﬂuenza B seasons. For the
other strains, there were not many seasons in each
group, but the trend was as expected. Seasons with
H1N1 and no dominant virus had low impact in terms
of excess mortality and R estimates, and the impact
varied when there was more than one dominant virus.
ILI data divided into age groups were only avail-
able from the 2001 season and onwards, and have not
been used in the analysis. Hiwever, age-grouped data
for overall deaths were available for all years from
1975 to 2004. The analysis of these data showed that
the eﬀect of the inﬂuenza outbreaks on overall mor-
tality was highest in the two lowest age groups, and in
the o65 years group. Most of the excess mortality
was attributed to theo65 years group.
Estimation of inﬂuenza-related excess mortality has
been done in other countries using similar Poisson
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panel) and new (lower panel) reporting system. The threshold value accounts for the ever-present baseline of ILI cases, also
observed oﬀ-season.
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regression-based methods; for example on data from
1976 to 1999 in the USA [8], 1990–1999 in Canada [5],
and 1996–1999 in Hong Kong [9]. The US study
estimated that on average the number of inﬂuenza-
related deaths formed 2.2% of all deaths, while in the
Canadian study the corresponding estimate was 1.9%,
compared to our estimate of 2.1%. In the Hong Kong
study, the estimate of inﬂuenza-related excess mor-
tality was 16.4 deaths/100 000 population, compared
to our estimate of 21.3/100 000 in the Norwegian
population. These ﬁndings are not dissimilar from
European studies using diﬀerent methods to estimate
the excess mortality: a German study for 1985–2001
[10, 11] estimated the excess mortality as 16.1 and 17.4
deaths/100 000 population for two study periods, and
a Czech study for 1982–2000 [15] estimated the excess
mortality as 2.2% of all deaths. Our estimates
for excess mortality in the o65 years group of 140
and 158 deaths/100 000 are comparable with studies
from Canada (108.8/100 000 population) [5], USA
(132.5/100 000 population) [8], and Hong Kong
(136.1/100 000 population) [9].
Most previous estimates of the reproduction
number R have been made for pandemic inﬂuenza,
but results from some studies are comparable to our
estimates. Using a model based on the Asian 1957–
1958 inﬂuenza A(H2N2) pandemic in the USA, R0
was estimated as 1.68 [26], while other studies esti-
mated R for inter-pandemic years as 1.39 [27], or in
the range between 1.2 and 1.8 [28]. These estimates
Table 1. Estimated excess mortality for each inﬂuenza season, together with numbers of reported ILI cases,
estimated reproduction number R and dominant virus type
Season
Est. excess
mortality
Total ILI
per 100 000 Rˆ (95% CI) Dominant virus
1975/1976 1251 22 076 1.30 (1.17–1.43) A/Victoria/3/75 (H3N2)
1976/1977 347 22 367 1.35 (0.55–2.46) A/Victoria/3/75 (H3N2)
1977/1978 651 20 061 1.32 (1.05–1.62) A/USSR/90/77 (H1N1) and A/Texas/1/77 (H3N2)
1978/1979 912 18 022 1.22 (1.00–1–46) B/Singapore/222/79
1979/1980 217 23 087 1.02* (1.00–1.04) No dominant virus
1980/1981 1036 18 696 1.36 (1.25–1.47) A/Bangkok/1/79 (H3N2)
1981/1982 573 24 174 1.00* (0.06–2.71) B/Singapore/222/79
1982/1983 422 21 532 1.20 (1.13–1.26) Sporadic outbreaks of H3N2 and H1N1
1983/1984 831 19 721 1.09 (1.05–1.12) B/USSR/100/83
1984/1985 1605 18 798 1.31 (1.00–1.65) A/Victoria/6/84 (H3N2)
1985/1986 1016 17 359 1.08 (1.04–1.11) B/Ann Arbor/1/86
1986/1987 510 18 089 1.20 (1.09–1.31) A/Singapore/6/86 (H1N1)
1987/1988 666 22 040 1.07 (1.01–1.13) B/Victoria/2/87
1988/1989 909 18 616 1.31 (1.10–1.54) A/Sichuan/2/87 (H3N2)
1989/1990 1291 17 969 1.21 (0.97–1.47) A/Sichuan/2/87 (H3N2) and B/Victoria/2/87
1990/1991 1044 15 956 1.10 (1.05–1.14) B/Yamagata/16/88
1991/1992 1303 19 829 1.35 (1.03–1.71) A/England/261/91 (H3N2)
1992/1993 589 19 914 1.06 (1.02–1.09) B/Panama/45/90
1993/1994 1802 15 230 1.42 (1.22–1.63) A/Hong Kong/23/92 (H3N2)
1994/1995 621 18 734 1.15 (1.14–1.17) B/Beijing/184/93
1995/1996 1077 16 012 1.36 (1.22–1.50) A/Johannesburg/33/94 (H3N2)
1996/1997 1426 15 746 1.51 (0.91–2.24) A/Wuhan/359/95 (H3N2) and B/Beijing/184/93
1997/1998 859 14 073 1.45 (1.30–1.60) A/Wuhan/359/95 (H3N2) and A/Sydney/5/97 (H3N2)
Season
Est. excess
mortality
Mean ILI
per 100 Rˆ (95% CI) Dominant virus
1998/1999 1403 1.93 1.29 (1.21–1.37) A/Sydney/5/97 (H3N2)
1999/2000 1526 1.91 1.69 (1.07–2.45) A/Moscow/10/99 (H3N2)
2000/2001 339 0.89 1.11 (1.07–1.15) A/New Caledonia/20/99 (H1N1)
2001/2002 746 1.32 1.13 (1.11–1.15) A/Panama/2007/99 (H3N2)
2002/2003 392 0.96 1.11 (0.96–1.26) No dominant virus
2003/2004 1025 1.55 1.43 (1.08–1.83) A/Fujian/411/2002 (H3N2)
ILI, Inﬂuenza-like illness ; CI, conﬁdence interval.
* Estimated breakpoint not signiﬁcant (no outbreak).
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correspond well to our estimates, which ranged from
about 1 in seasons with no obvious inﬂuenza outbreak
to a maximum of 1.69.
The Poisson regression-based models proved suit-
able, adjusting for available markfor inﬂuenza ac-
tivity and seasonality in week-to-week data. In classic
epidemic-threshold models, the excess mortality is
deﬁned as all deaths exceeding a seasonal baseline
threshold, based on years with low inﬂuenza activity
[5]. This baseline can be found for instance by cyclic
regression [10, 12–14]. Although seemingly robust,
these models do not utilize available inﬂuenza data as
well as Poisson regression-based models [11]. The
diﬀerences in the Poisson regression-based models are
mostly due to the type of surveillance measurements
available for inﬂuenza, the types of seasonal marker,
and the resolution of the data. The Norwegian data
diﬀer from the other Poisson-regression based studies
mentioned by using the rate of ILI consultations
from general practitioners as the marker for inﬂuenza
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Fig. 3. Estimated excess mortality against R for each inﬂuenza season, marked by dominant virus type.
Table 2. Regression results and estimated excess mortality for separate analyses on age groups, and for the overall
analysis
Dataset Age group bILI S.E. P value
Mean est.
excess mortality
Rate per
100 000
1975–1998 0–4 0.00051 0.00019 0.0065 8 2.9
5–14 0.00072 0.00039 0.066 3 0.6
15–64 0.00024 0.000054 <0.0001 56 2.1
o65 0.00076 0.000029 <0.0001 834 138.1
All 0.00068 0.000027 <0.0001 911 21.7
1998–2004 0–4 0.046 0.020 0.020 8 2.6
5–14 0.053 0.042 0.21 3 0.4
15–64 0.0032 0.0046 0.49 13 0.4
o65 0.038 0.0029 <0.0001 879 136.0
All 0.033 0.0027 <0.0001 905 20.4
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activity, instead of virological laboratory conﬁr-
mations [8, 9] or inﬂuenza-certiﬁed deaths [5]. We
found that the rate of ILI consultations, together with
seasonal and year-to-year markers, modelled overall
mortality satisfactorily.
In Poisson regression-based methods one can
adjust for several variables in addition to diﬀerent
markers for inﬂuenza activity, e.g. other variables
which inﬂuence mortality, and seasonal and year-to-
year markers. Other possible explanatory variables
include : dominant virus type, temperature, human
respiratory syncytial virus (RSV) and other sub-
categories of overall death. Models with such ad-
ditional explanatory variables and factor groups were
explored.
Information about dominant virus types was better
used as a supplement rather than including it in the
model because viruses co-dominate and vary in mag-
nitude between seasons. This leaves the year-to-year
variability to be covered by the season variable.
Temperature is often mentioned as an explanatory
factor for overall death [29], but is unfeasible to use in
Norway due to geographical and meteorological
variability. Using the weekly average temperature in
Oslo as a covariate gave a very small but signiﬁcant
impact ; the reduction in over-dispersion was minimal
and the results were broadly unchanged. For RSV
infections, there are no consistent national data
available, and RSV outbreaks rarely coincide with
inﬂuenza outbreaks.
For our data a lag of 1 week between ILI activity
and mortality gave the best model ﬁt. A 1-week lag
was also used in other similar analysis [5]. Using
months instead of weeks to control for seasonality has
been done in other studies [5], but in our case this
weakened model ﬁt.
Clinical surveillance data on ILI were collected
from all general practices in primary care for 1975–
1998 and from selected sentinels for the period 1998
onwards. Completeness of data may pose a problem
for the ﬁrst period for which we did not collect any
denominator data. However, coverage has been esti-
mated to be constant over the years with about 60%
of the practices reporting every week. For the second
period we did collect denominator data, and varia-
bility in completeness was not aﬀected as much.
Clinically reported ILI, rather than laboratory
conﬁrmations, was chosen as a proxy for inﬂuenza
activity. Laboratory diagnostics and their use have
been developing over the study period and extensive
data on laboratory conﬁrmations in Norway are only
available from 1999 onwards. These data show that
the trends in the number of virus conﬁrmations
matched the ILI numbers well in seasons with obvious
outbreaks, but in seasons with low inﬂuenza activity
the ﬁt is less good. In these seasons laboratory detec-
tions of inﬂuenza reﬂect not only inﬂuenza activity,
but also laboratory testing activity due to outbreaks
of other respiratory pathogens. As long as sampling in
a population is representative, data on laboratory
conﬁrmations may serve well in some countries, but in
Norway this information comes from a limited num-
ber of laboratories, and the testing practice and sen-
sitivity varies widely from season to season and in the
diﬀerent laboratories. The ILI data are more robust
for other factors, and the good agreement detected
between ILI and mortality was not detected using
laboratory data, as seen by a worse model ﬁt when
explaining mortality using laboratory data in the
available period with a Poisson model. Although ILI
consultation rates do not reﬂect the true rates of
inﬂuenza in absolute numbers, they do reﬂect the
epidemic curve. This is supported by the coincidence
of peaks of ILI and excess mortality during seasons
with large inﬂuenza outbreaks, as well as the agree-
ment between peaks of ILI and the numbers of
laboratory conﬁrmations in such seasons, where data
are available. The clinical deﬁnition of inﬂuenza has
not changed in Norway over the years and is the
same nationwide. Consequently regional and tem-
poral biases are not expected. However, during each
seasonal outbreak clinicians may be more inclined to
use the R80 Inﬂuenza diagnosis when they know
inﬂuenza virus is circulating, thereby enlarging the
size of the peak, but the time period for the peak will
not shift. Altered health-seeking behaviour over the
years may aﬀect the total number of ILI cases per
season but would probably not change suﬃciently
quickly during a single season to alter the shape of the
outbreak curve. Hence, we do not believe it would
aﬀect the relationship with mortality.
The ‘epidemiological week’ of the ILI surveillance
was recorded from Friday to Thursday, 3 days earlier
than the calendar week (in Norway: Monday–
Sunday). As we tried diﬀerent lag times between ILI
and death, and found that 1 week gave the best ﬁt, this
should not inﬂuence the result.
The agreement of ILI and mortality in terms of
peak and initial rise, and of ILI and laboratory data in
seasons with obvious inﬂuenza outbreaks, suggests
that ILI is also a suitable variable for estimating re-
production numbers. The Norwegian laboratory data
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are not suﬃciently robust for such an estimation, and,
where available, will tend towards overestimation
(especially for seasons with low activity). However,
the R estimates based on ILI data have some potential
sources of bias. Unexpected decrease in ILI activity
was found around Christmas and New Year in some
seasons, probably due to lower registration in the
holidays. These artefacts would be covered by the
week-to-week markers when estimating excess mor-
tality, but could cause some underestimation of R
in seasons where the ILI peak is around New Year.
There is a potential for overestimation due to clin-
icians being more inclined to use the inﬂuenza diag-
nosis during certain periods. Estimating R from the
initial growth of the outbreak would not be as
vulnerable for such bias as methods using the entire
epidemic curve in the estimation. Asynchronous
inﬂuenza epidemics across Norway would also be a
source of bias, but surveillance data suggests that, for
most seasons, epidemics are concurrent. At worst,
epidemics may be displaced by 1–2 weeks for parts of
the outbreak between the most distant regions. The
assumptions of an incubation and infectious period
also represent some uncertainty, while the uncertainty
from the regression estimating the initial growth rate
is quantiﬁed through 95% CIs for R. However,
reproduction numbers are important quantities for
measuring the impact of and comparing outbreaks,
and they are central in modelling the impact of
counter-measures. Few estimates for seasonal inﬂu-
enza are available in the literature, and the estimates
from the Norwegian data serve as a useful addition.
Our results ﬁt well with existing estimates, which is an
interesting ﬁnding in itself, and further proves that it
is possible to estimate reproduction numbers using
clinically reported ILI data.
In conclusion, the Poisson regression-based
methods proved useful in explaining the number
of overall deaths per week by reported ILI cases.
Reproduction numbers R, estimated using reported
ILI cases, ranged up to about 1.7, supporting results
found by studies using diﬀerent methods. Overall,
inﬂuenza was estimated to contribute to more than
2% of all deaths in Norway.
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Abstract
When applying survival analysis, such as Cox regression, to data from
major clinical trials or other studies, often only baseline covariates are used.
This is typically the case even if updated covariates are available throughout
the observation period, which leaves large amounts of information unused.
The main reason for this is that such time-dependent covariates often are
internal to the disease process, as they are inﬂuenced by treatment, and
therefore lead to confounded estimates of the treatment eﬀect. There are,
however, methods to exploit such covariate information in a useful way.
In this paper we study the method of dynamic path analysis applied to
data from the Swiss HIV Cohort Study. To adjust for time-dependent con-
founding between treatment and the outcome ‘AIDS or death’, the analysis
is done on a sequence of mimicked randomized trials constructed from the
original cohort data. To analyse these trials together, regular dynamic path
1
analysis is extended to a composite analysis of weighted dynamic path mod-
els. Results using a simple path model, with one indirect eﬀect mediated
through current RNA level, show that most, or all, of the total eﬀect go
through RNA for the ﬁrst four years after treatment start. A similar model,
but with CD4 level as the mediating variable, show a weaker indirect eﬀect,
but the results are i the same direction. There are many reasons to be
cautious about making to conclusive statements about estimates of direct
and indirect eﬀects, such as the ones from dynamic path analyses. Dynamic
path analysis is however a useful tool to explore underlying processes which
are ignored in regular analyses. Such analyses of direct and indirect eﬀects
also usually have a more provisional status, and may not require the same
level of certainty.
1 Introduction
Survival analysis has established itself as a major tool in clinical research. Re-
cently, it was demonstrated to be the most commonly used of the more advanced
statistical methods in the New England Journal of Medicine [1]. However, a sur-
prising aspect of survival analysis as practiced in medical applications and other
ﬁelds is the lack of attention to covariate information collected between the start-
ing point and the event. Commonly, one sees major clinical trials and other studies
where the main analysis is a Cox regression using only baseline covariates; this in
spite of the fact that many of these covariates are updated repeatedly throughout
the period of observation. Clearly, large amounts of useful information are not
being used.
It is not hard to understand the reasons behind this situation. Typically,
these covariates will be internal to the disease process; they will be inﬂuenced by
a possible treatment eﬀect, and therefore they will, so to speak, ‘steal’ treatment
eﬀect from the event analysis. Thus, when a time-dependent Cox model is run the
treatment eﬀect will typically be underestimated. This is a very well known prob-
lem and one is thoroughly warned against it in the survival analysis literature, see
e.g. [2]. Nevertheless, it is a waste of information to ignore time-dependent covari-
ates and there exist procedures for exploiting this information, see e.g. dynamic
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path analysis as described in [3, 4].
More fundamentally, the skeptical attitude to detailed analysis of time-dependent
covariates is that this pertains to the issue of how the treatment eﬀect is medi-
ated towards its ﬁnal goal of (possibly) prolonging survival. More, precisely, in a
dynamic path analysis we attempt to estimate indirect eﬀects of treatment medi-
ated through one or more markers, or time-dependent covariates. Such mediation
problems are vulnerable to unmeasured confounders, and are in general depen-
dent on some prior mechanistic understanding. Nevertheless, such analysis could
contribute in a valuable way to understanding the mechanisms behind treatment
eﬀects.
It is important to realize that in biomedical research, mechanistic understand-
ing is typically limited. A new medication, for example, may be suggested because
the mechanistic knowledge suggests that it should have a positive eﬀect. However,
one can never be sure that it lives up to expectations. There are numerous exam-
ples of treatments that have reached even the level of phase III clinical trials, but
do not yield the expected results. See, for example, Rossebø et al. [5] where ex-
tensive cholesterol reduction does not achieve the aim of limiting the progression
of aortic stenosis. One reason for such a negative result is that biological path-
ways are very complex. Medical interventions, such as taking a medication, may
typically have the eﬀect of blocking certain receptors, that is, of blocking certain
paths in the pathway system. However, the eﬀect of such interventions will tend
to have many types of eﬀects, following many pathways and the net result may
not be as expected.
The uncertainty within mechanistic understanding of biological systems means
that one should use all statistical information available to throw more light on
mechanistic issues. This includes, for example, using repeated measurements
taken during the study in clinical survival studies. This may contribute to under-
standing, even though the causal issues may not be clariﬁed.
In the present paper we consider a situation more complex than standard sur-
vival analysis. Analysing HIV cohort data, we are faced with the fact that treat-
ment start is dependent on the state of the patient; treatment is rarely started
unless the infection has shown progression by eﬀecting the immune system, mea-
sured for example by the CD4 cell count. This creates time-dependent confound-
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ing between treatment and CD4 count. We use a method for resolving this issue,
based on mimicking a series of randomized trials from the original cohort data,
proposed in Gran et al. [6]. We then study how dynamic path analysis can be
used together with these ideas, to gain more insight into how the treatment eﬀect
is mediated.
Dynamic path analysis is an extension of classical path analysis, where the vari-
ables can be time-dependent. The ﬁnal outcome is a stochastic process, typically
a counting process in a survival or event history setting. Dynamic path analysis
can be used to describe how the eﬀect of a ﬁxed covariate, such as treatment,
works directly and partly indirectly, through time-dependent covariates. The aim
is to decompose the total eﬀect of treatment into a sum of indirect eﬀects, which
are mediated through time-dependent covariates, as well as the direct eﬀect.
Note, as stated in [7], that there exists no unique deﬁnition of the concepts of
direct, indirect and total eﬀects, and that unmeasured confounders could cause
problems to the interpretation of such concepts. Nevertheless, dynamic path
analysis is a useful tool for understanding how the treatment eﬀect on a time to
event endpoint is mediated through time-dependent covariates.
When analysing many mimicked randomized trials, composite likelihood in-
ference [8–10] serve as a simple and eﬃcient method for combining the diﬀerent
analyses, and giving overall eﬀect estimates. The parameters based on such infer-
ence would also keep their interpretation, given certain assumptions.
In Section 2 we describe the dataset from the Swiss HIV Cohort study, while
the approach for constructing mimicked randomized trials is described in Section
3. The dynamic path model and path eﬀects are presented in Section 4, while the
estimators for these path eﬀects follow in Section 5. In section 6 we apply our
methods to the Swiss cohort data, with a discussion following in Section 7.
2 The Swiss HIV cohort dataset
The methods in this paper are applied to data from the Swiss HIV Cohort
Study [13], which is an ongoing multi-center research project following up HIV
infected adults aged 16 or older. The data begins in January 1996, when Highly
active antiretroviral treatment (HAART) became available in Switzerland, and
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run until September 2003. The time scale used is months since the start of follow
up, with baseline being the time of the ﬁrst visit after January 1996. Patients who
died or refused further participation before 1996, who were on HAART or in in
clinical stage C at baseline, or whose treatment history before joining the cohort
was uncertain were excluded. Time between visits varies, but scheduled clinical
follow-up is every sixth month, with additional laboratory measures taken every
third month. On months without visits, the last observation is carried forward.
The variables measured include CD4 count, HIV-1 RNA and haemoglobin levels,
together with indicator variables describing whether the individuals have been
treated with mono therapy, dual therapy or HAART, or experienced a CDC stage
B event (a disease associated with HIV but less severe than an AIDS deﬁning dis-
ease). When individuals ﬁrst start treatment they are considered as on treatment
from that time and until the end of the study.
The dataset consists of data from 2161 individuals, who were observed over
a maximum of 92 months. The total number of person-months of observation is
77 838. Two hundred and two of the individuals progressed to AIDS or death,
while 717 were never treated with HAART. The dataset used is the same as was
analyzed in Sterne et al. [14] and in Gran et al. [6].
3 Mimicking randomized trials
3.1 Constructing a proper pseudo dataset
When analysing the Swiss HIV Cohort data we handle the problem of time-
dependent confounding, represented by variables such as the HIV-1 RNA and
CD4 cell count, by analysing a sequence of mimicked randomized trials, as was
done in Gran et al. [6].
Each mimicked trial is constructed based on individuals starting treatment
in a certain time interval or, as in our situation, in a certain month since start
of follow-up. Individuals starting treatment in that particular month serve as
the treatment group, while the individuals not yet on treatment serve as the
control group. To avoid confounding due to treatment, individuals in the control
group are artiﬁcially censored at the time of later treatment start. Only baseline
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covariates and covariates at the start of each mimicked trial are controlled for in
the analysis of each such subset of the real data. Dependent censoring, which
might be introduced when constructing the pseudo datasets, as well as other
dependent censoring, is adjusted for using inverse probability of censoring (IPC)
weights.
The purpose of the weighting procedure is to produce a weighted dataset which
reﬂects most of the mechanisms of the unweighted dataset, but for which the
censoring can now be considered as independent.
Let A be an indicator for initiating treatment at the start of the mimicked trial
(valued 1 if treated and 0 otherwise), C(t) an indicator for the combined event
‘censoring or artiﬁcial censoring’ at time t (1 if censored and 0 otherwise), Z a
vector of time-independent baseline covariates, L(t) a vector of time-dependent
covariates at time t, and L¯(t) the time-dependent covariate history up to time
t. The IPC weight wi(t) for individual i at time t, weighting for both regular
censoring and the artiﬁcial censoring done when creating the pseudo dataset, can
be constructed as the IPC weights in Robins et al. [11] and Hernan et al. [12],
using
wi(t) =
t∑
k=0
P (C(k) = 0|C¯(k − 1) = 0, A = ai,Z = zi)
P (C(k) = 0|C¯(k − 1) = 0, A = ai, L¯(k − 1) = l¯i(k − 1))
, (1)
where by deﬁnition C¯a(−1) = 0.
Let μi(s) be the censoring intensity for individual i, conditioned on its full co-
variate history. If the covariates and events are observed in discrete time intervals,
where tk is the end time of the kth interval, we can approximate the denominator
in (1) by
P (C(k) = 0|C¯(k − 1) = 0, A = ai, L¯(k − 1) = l¯i(k − 1)) ≈ exp(−
∫ tk
tk−1
μi(s)ds).
Correspondingly, given that μ˜i(s) is the censoring intensity for individual i con-
ditioning on its marginal covariate history, we can approximate the numerator in
6
(1) by
P (Ca(k) = 0|C¯a(k − 1) = 0, A = ai,Z = zi) ≈ exp(−
∫ tk
tk−1
μ˜i(s)ds).
In other words, we can use that
wi(t) ≈ exp(−
∫ t
o
μi(s) − μ˜i(s)ds),
where μi(s) and μ˜i(s) can be estimated using Aalen’s additive regression model [4].
3.2 Interpretation of the censoring weights
Imagine that the unweighted data for a mimicked randomized trial is distributed
according to some probability measure P . As mentioned in Section 3.1, the cen-
soring done to create this dataset could be dependent, leading to biased estimates.
We adjust for such bias using the weights wi(t). It is natural to interpret these
weights as a likelihood ratio process.
More precisely, we consider a new probability measure Q that is absolutely
continuous with respect to P . Q diﬀers from P in that the censoring is inde-
pendent, but the behavior of the remaining processes is left unchanged. The
likelihood ratio between the measure P and Q, over the history before time t,
gives the weight at time t. It is interesting to note that our approximation of
the weights suggested by Robins et al. [11] coincide asymptotically with a special
case of the well known Jacod formula for likelihood ratios. These aspects of data
re-weighting are discussed in [15].
4 Dynamic path model and path eﬀects
If the censoring is independent, then the mimicked randomized trials in Section
3.1 can be analysed using dynamic path analysis as it was proposed by Fosen et
al. [3]. Let us start with the analysis of one such mimicked trial.
We will consider a simple dynamic path model, a model with one direct and
one indirect path going from treatment to the main event ‘AIDS or death’. The
7
indirect path is mediated through a time-dependent continuous covariate. We will
in two separate analyses consider models with both the RNA and CD4 level as the
mediating variable. The RNA variable gives a measure of the amount of HIV-1
RNA in the blood of the HIV infected individual, while the CD4 variable measure
the number of CD4 immune cells.
Let Ai be the treatment indicator for individual i, Li(t) the level of the medi-
ating variable (either the RNA or CD4 level) for individual i at time t, Zi a vector
of relevant baseline covariates for individual i, and Di(t) an indicator function, 1
if individual i dies or is diagnosed with AIDS at time t, and 0 otherwise. We have
n independent observations Ai, Li(t), Zi, and Di(t), of A, L(t), Z = (Z1, ..., Zp),
and D(t), where p is the number of baseline covariates. The model is illustrated
by the dynamic path diagram [3] in Figure 1.
Figure 1: Path diagram for the dynamic model with a direct path from treatment A
to the increment of the event process dD(t) (AIDS or death) and an indirect
path from A to dD(t) through a mediating variable L(t), being either the
HIV-1 RNA level or the CD4 cell count. α2(t), β2(t) and β3(t) are regression
coeﬃcients.
Considering the path diagram, we observe two paths going from treatment A
to the event increment dD(t); one direct path, and one indirect path through the
time-dependent covariate L(t). As in [3], the aim is to analyse the eﬀect of the
covariate processes on the inﬁnitesimal changes of the event process D(t), dD(t).
The dynamic path analysis is carried out using recursive least squares regression,
as in regular path analysis. Each node in the diagram is regressed onto its parent,
for each time t when data is potentially collected. As previously mentioned, if
data for a time-dependent covariate is not available, the last observation is carried
forward, as in [14]. In contrast to regular path analysis, the regression of the event
D(t) onto its parents is done using the additive regression model. Direct and
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indirect eﬀects can now be calculated, preserving the additivity of classical path
analysis, allowing total eﬀects to be decomposed into direct and indirect eﬀects.
An indirect eﬀect is simply deﬁned as the product of the regression functions
(ordinary linear or additive) along its path.
The model in Figure 1 is formally given by
L(t) = α1(t) + α2(t)A + α3(t)Z + M1(t) (2)
for all t ∈ {1, 2, ..., 92}, and
D(t) =
∫ t
0
Y (s)
(
β1(s) + β2(s)A + β3(s)L(s−) + β4(s)Z
)
ds + M2(t), (3)
where Y (t) is the at risk indicator at time t (valued 1 if at risk and 0 otherwise),
Mh(t) are martingales corresponding to the residuals, αj(t) for j ∈ {1, 2, 3} are
regression coeﬃcients at time t, and βk(t) for k ∈ {1, 2, 3, 4} are regression func-
tions. See for example Diggle et al. [17] for other models for longitudinal data
formulated using martingale residuals.
The parameters α(t) = (α1(t), α2(t), α3(t)) in model (2) can be estimated
using ordinary linear regression at each time t ∈ {1, 2, ..., 92}, and the parameters
β(t) = (β1(t), β2(t), β3(t), β4(t)) in model (3) using additive hazard regression.
We deﬁne the two cumulative path eﬀects
A → D :
∫ t
0
β2(s)ds (4)
and
A → L → D :
∫ t
0
α2(s)β3(s)ds (5)
as the direct eﬀect of treatment on the outcome, (A → D), and the indirect
eﬀect of treatment going through the variable L, (A → L → D). In other words,
direct and indirect eﬀects along paths such as the ones in Figure 1 are found by
multiplying the regression coeﬃcients along that path. In Fosen et al. [3], it is
shown that these path eﬀects add up to the marginal (only baseline adjusted)
eﬀect.
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5 Estimators for the path eﬀects
5.1 Weighted dynamic path analysis
If it was not for the censoring, we could proceed as in [3] to introduce estimators for
the path eﬀects analysing one mimicked randomized trial alone. We will, however,
do a weighted analysis to adjust for any dependent censoring, which corresponds
to using data distributed according to P to do inference for Q (remembering the
notation of Section 3.2).
Let us ﬁrst introduce some more notation. Let Nk(t) be a vector where the
ith element Nk,i(t) is the number of events (indicated by Di(t) = 1) up until time
t for individual i in trial k. Xk(t) is a matrix where the ith element, Xk,i(t) =
(1, Ak,i,LTk,i(t−),ZTk,i), is a vector with all covariate values at time t for individual
i in trial k and Yk(t) is a vector where the ith element, Yk,i(t), is the ‘at-risk’
indicator at time t for individual i in trial k.
Consider the additive hazard regression model from Equation 3 with respect to
Q. We have a left continuous function B(t) = (
∫ t
o β1(s)ds,
∫ t
0 β2(s), β3(s), β4(s)),
such that
Mk(t) = Nk(t) −
∫ t
0
Yk(s)Xk(s)dB(s)
is a Q-martingale with respect to the history of the individuals in trial k.
Let Wk(t) be a diagonal matrix where the ith element along the diagonal
Wk,i(t) is the censoring weight at time t for individual i in trial k, and recall the
discussion in 3.2. Since Wk(t) is the likelihood ratio process, we obtain from the
integration-by-parts formula for stochastic integrals that
∫ t
0
Wk(s−)dNk(s) −
∫ t
0
Wk(s−)Yk(s)Xk(s)dB(s)
deﬁnes a P -martingale. This suggests that some reasonable estimator for B(t),
say B̂(t), is given by each of the estimating equations
Xk(t)T Wk(t−)dNk(t) − Xk(t)T Wk(t−)Yk(t)Xk(t)dB̂(t) = 0 (6)
for every t.
For each trial k and every jump time t of Lk, and for the mediating covariate
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processes Lk(t), we have the linear model
Lk(t) = Xk(t)α(t) + k(t),
where k(t) has zero mean and its components are uncorrelated with respect to
Q.
Now,
Wk(t)
(
Lk(t) − Xk(t)β(t) + k(t)
)
has zero mean and its components are uncorrelated with respect to Q.
The corresponding weighted normal equation is
Xk(t)T Wk(t)Lk(t) − Xk(t)T Wk(t)Xk(t)β̂(t) = 0. (7)
Estimates of α(t) and B(t), αˆ(t) and Bˆ(t), inserted into equation (4) and (5)
suggests the estimators
A → D : B̂2(t) (8)
and
A → L → D :
∫ t
0
α̂2(s)dB̂3(s) (9)
for the cumulative path eﬀects at time t. B̂l(t) is the lth entry of B̂(t).
5.2 Estimating composite treatment eﬀects combining all
mimicked trials
Until now we have considered the dynamic path analysis of one mimicked ran-
domized trial, where in the last section we extended the dynamic path analysis
from [3] by introducing censor weights. However, aiming to analyse the full cohort
dataset, we construct many mimicked randomized trials; one for each possible time
of treatment start. We therefore seek to combine many such weighted dynamic
path analyses, in a similar way as was done with the Cox regressions in [6], by
using composite likelihood inference.
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Composite additive hazard regressions
Let us ﬁrst combine the additive regressions done for each mimicked trial. In
order to combine all the mimicked trials to get an overall estimate, we aggregate
over the estimating equations (6), resulting in the the estimating equation
∑
k
Xk(s)T Wk(s−)dNk(s) −
∑
k
Xk(s)T Wk(s−)Xk(s)dB̂(s) = 0.
A short matrix computation shows that the corresponding aggregated estimator
is
B̂(t) =
∑
k
∫ t
0
(∑
l
Xl(s)T Wl(s−)Xl(s)
)−1
Xk(s)T Wk(s−)dNk(s). (10)
Composite linear regressions
Correspondingly, we must aggregate the weighted normal equations (7) for all
observed time points in each mimicked trial. This gives the aggregated estimation
equation ∑
k
X(t)Tk Wk(t)L(t)k − X(t)Tk Wk(t)X(t)kβ̂(t) = 0,
and the estimator
β̂(t−) = ∑
k
(∑
l
X(t)Tl Wl(t−)X(t)l
)−1
X(t)Tk Wk(t−)L(t)k. (11)
Estimating cumulative path eﬀects
The estimators (10) and (11) can now be used in (8) and (9), giving estimators
for the aggregated path eﬀects. Conﬁdence intervals, or more precisely percentile
intervals, are calculated using bootstrap re-sampling methods [18], re-sampling at
an individual level on all the data used in the composite analysis.
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6 Results
6.1 Mimicked randomized trials constructed from the Swiss
HIV Cohort data
Using the data from the Swiss HIV Cohort Study we construct 92 mimicked
randomized controlled trials, as in [6]. Figure 2 show the mean levels of RNA and
CD4, together with individual trajectories, for the treatment and control group in
the ﬁrst mimicked trial. The choice of trial is arbitrary, and other trials generally
show a similar trend.
Figure 2 illustrates how the RNA levels quickly decrease for individuals re-
ceiving treatment, before stabilizing. The CD4 level for individuals on treatment
increases, but does not stabilize as fast as the RNA level. In the control group,
the RNA and CD4 levels are quite stable. Note that the RNA and CD4 variables
used in the following analyses take the same form as in Figure 2. The RNA level
is measured as the logarithm of HIV-1 RNA copies per millilitre and the CD4
level is the square root of CD4 cells per microlitre.
6.2 Results using a model with an indirect treatment ef-
fect through the RNA level
Let us ﬁrst consider the model in Section 4 with RNA level at time t as the
mediating variable, and perform a composite weighted dynamic path analysis of
all the mimicked randomized trials. We now seek to estimate the indirect eﬀect
of treatment through RNA, together with the remaining direct eﬀect, using the
estimators from Section 5.2. As noted earlier, the indirect and direct eﬀect add up
to the total eﬀect. The baseline covariates used, corresponding to the vector Z in
the equations, include sex, risk group, age at baseline and the following covariates
at inclusion, at the start of the mimicked trial and lagged values at the start
of the mimicked trial: CD4 group (grouped into 0-49, 50-99, 100-199, 200-349,
350-499, 500-749, ≥ 750 cells per μL), RNA group (grouped into <400, 400-
1000, 1001-10 000, 10 001-100 000, >000 000 copies per mL), haemoglobin group
(grouped into ﬁfths), CDC B event and previously experienced CDC B event.
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Figure 2: RNA and CD4 levels for individuals starting treatment and the controls in
the ﬁrst mimicked randomized controlled trial. The black line is the mean
RNA or CD4 level at a certain time point, while gray lines indicate individual
trajectories.
Lagged values are values three months before, corresponding to the scheduled
time between visits [14]. All programming was done in the statistical package R,
version 2.10.1 [19]. Estimated cumulative eﬀects, and the corresponding regression
functions (not cumulative), are plotted in Figure 3.
The ﬁrst three panels of the ﬁgure, with plots of the total eﬀect and the two
path eﬀects, show that there is a fairly constant indirect eﬀect of treatment going
through RNA for the ﬁrst 4 years after treatment start. After that, the eﬀect
decreases. The direct eﬀect of treatment is close to zero for the ﬁrst 3-4 years,
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Figure 3: Estimated cumulative direct and indirect eﬀects, and regression functions,
from the composite weighted dynamic path analysis using the model in Fig-
ure 1. Grey lines represent 95% percentile intervals based on 100 bootstrap
replications. Note that the last two panels are regression functions, which
are not cumulative, corresponding to the parameters α2(t) and β3(t) respec-
tively.
before there is a corresponding shift towards an increasing direct eﬀect. We see
that the uncertainty, represented by the 95% percentile intervals, grows larger to
the right as fewer people are left observed.
In the two last panels of Figure 3 we see the regression functions for the
treatment eﬀect on RNA and the RNA eﬀect on the event ‘AIDS or death’, or
α2(t) and β3(t) from the equations in Section 4 and in Figure 1. We see that
the eﬀect of treatment on RNA appears to be immediate, and then it remains
constant, or possibly slowly decreases. The RNA eﬀect on the event ‘AIDS or
death’ on the other hand, is fairly constant. The regression functions in the two
last panels are cut after 80 months, to remove the noise from the uncertainty at
the end to better see the development in the ﬁrst 80 months.
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6.3 Results using a model with an indirect treatment ef-
fect through the CD4 level
Let us then consider the same model as in the previous section, but with CD4 level
as the mediating variable instead of RNA. The results from a composite weighted
dynamic path analysis is presented in Figure 4. As in the previous ﬁgure, the three
top panels show the cumulative total, direct and indirect eﬀect, while the bottom
two panels show the regression functions α2(t) and β3(t) from the equations in
Section 4.
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Figure 4: Estimated cumulative direct and indirect eﬀects, and regression functions,
from the composite weighted dynamic path analysis using the model in Fig-
ure 1. Grey lines represent 95% percentile intervals based on 100 bootstrap
replications. Note that the last two panels are regression functions, which
are not cumulative, corresponding to the parameters α2(t) and β3(t) respec-
tively.
At ﬁrst glance, the results from Figure 4 are very similar to the results using
RNA as the intermediate variable. We see, however, that the indirect eﬀect of
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treatment going through the CD4 level is smaller than the indirect eﬀect through
RNA shown in Section 6.2. We also see that the regression functions for HAART
on CD4 and CD4 on the ﬁnal outcome ‘AIDS or death’ behave diﬀerently than
for the corresponding regression functions using RNA in the previous section.
An obvious diﬀerence between RNA and CD4 is that CD4 levels will decrease
while RNA levels will increase with worsened disease progression, but there is also
diﬀerences in how these levels behave. The treatment eﬀect on CD4 from Figure
4 seems to be working slower than the eﬀect on the RNA level and stabilizing
much later. The regression functions in the two last panels are again cut after 80
months.
7 Discussion
From the results analysing the Swiss HIV Cohort data in Section 6, we see that
using HIV-1 RNA level as the mediating variable in our dynamic path model
captures more of the total eﬀect than using the CD4 cell count. The direct
eﬀect plotted in Figure 3 actually suggests that most, or all, of the treatment
eﬀect can be explained by the RNA level for the ﬁrst three or four years after
starting treatment. After that, the indirect eﬀect of RNA levels oﬀ, and the direct
eﬀect increases. One interpretation of this would be that the treatment eﬀect is
explained by the RNA level for the ﬁrst three or four years after treatment start,
while after that other factors become more important. An explanation to why
the eﬀect decreases after three or four years could be that patients on treatment
are more closely clinically monitored, and also more likely to receive prophylaxis
against opportunistic infections if indicated. Also, patients not (yet) on treatment
may have special characteristics with poorer outcomes (e.g. injecting drug use and
presumed poor treatment adherence). However, HAART, and especially protease
inhibitors, appear to have a number of eﬀects that are not necessarily mediated
through the eﬀect on viral replication [20–22], so it is not obvious that all eﬀects
are mediated through viral load.
The estimated direct and indirect eﬀect using CD4 level as the mediating
variable, found in Figure 4, point in the same direction as for the estimates using
RNA, but the eﬀect going through CD4 is smaller. From the plots of the regression
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functions in Figure 3 and Figure 4 of HAART eﬀect on RNA and CD4, we see
that treatment aﬀects the RNA level much more rapidly than the CD4 level.
Both levels stabilize a certain time after treatment start, but RNA stabilizes much
faster. This could be part of the explanation as to why the indirect eﬀect through
RNA is greater than the one through CD4. The same propensity to faster change
in RNA levels is also seen in the descriptive plots in Figure 2.
Note that when interpreting plots like the ones in Figure 3 and Figure 4, i.e.,
both time-dependent eﬀect estimates and estimated regression functions, the un-
certainty will increase towards the right because fewer observations are available.
This is reﬂected in wider conﬁdence intervals. In other words, the most reliable
information is found to the left in these ﬁgures.
There are reasons to be cautious about making conclusive statements about
estimates of direct and indirect eﬀects, such as those estimated using dynamic
path analysis. The most important reason could be that any possible confounding
between the mediator and the ﬁnal outcome will aﬀect the estimates. When
estimating total eﬀects, one needs to assume no unmeasured confounding between
exposure and the outcome; and when estimating direct and indirect eﬀects, there
should also be no unmeasured confounding between mediator and outcome [23].
These assumptions will therefore be harder to satisfy, and the problem will increase
with the number of mediators. As when estimating total eﬀects, assumptions of
no unmeasured confounders are generally not testable when estimating direct and
indirect eﬀects. See [24], where additional assumptions for eﬀect decomposition,
beyond the absence of confounders, are discussed. Note also that measurement
error in mediating variables often will cause indirect eﬀects to be underestimated
[25]. Another important point is that the estimated indirect and direct eﬀects are
based on a speciﬁed model, modelling how the variables aﬀect each other, and
will therefore depend on whether this model is a correct description of the actual
system of variables. This will also include how the variables are represented, for
example if they should be parameterized or dichotomized to be appropriate in a
linear model. As for the method of dynamic path analysis, one should note that
this still is a rather novel approach and that there remains a need to formalize
certain aspects of its use [7].
The main purpose of this paper is to explore methodological possibilities of
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dynamic path analysis. The present study is based on a rather limited number
of endpoint from the early years of antiretroviral treatment, suggesting that it
is premature to draw solid biological and clinical conclusions. However, despite
the reservations, there are still much insight to gain from dynamic path analyses
of direct and indirect eﬀects, including insight on processes which are ignored in
analyses of total eﬀects. One could argue that studies about direct and indirect
eﬀects usually have a more provisional status, and should not require the same
level of certainty as for studies of total eﬀects.
The dynamic path models used to analyse the data in this paper are simple
models including only one intermediate variable included at a time, namely the
level of RNA copies or CD4 cells. One would expect that antiretroviral treatment
would lower the RNA level, and have a positive eﬀect on the outcome ‘AIDS or
death’. Similarly, one would expect to see similar eﬀect if the RNA level was re-
placed with CD4 level, which is the most commonly used marker for HIV disease
progression. Biologically, one would expect that the eﬀect of antiretroviral treat-
ment on clinical progression is channeled via a path going through the RNA level
and then CD4 level. This would suggest more complex models, with both RNA
and CD4 included at the same time and with several possible indirect paths going
from treatment to the outcome. However, models with such paths would demand
more from the data to capture necessary details. Eﬀect estimates for such com-
plex paths will, for example, be more easily subject to confounding and harder to
interpret. The fact that laboratory measures are taken every third month at best
may weaken attempts to model the interaction between variables, such as RNA
and CD4 levels. We therefore chose to focus on two simple dynamic path models
in this paper, to demonstrate how the idea of mimicking randomized trials and
doing composite analyses in [6] can be used to extend the method of dynamic
path analysis and explore datasets such as the Swiss HIV Cohort data. We have
shown that even the most simple dynamic path models can be used to gain more
insight about underlying processes in such datasets.
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